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INTRODUCTION 
 
 Rheumatoid arthritis(RA) is a disease of joints. It is a type of inflammatory 
arthritis. Characterized by chronic symmetric erosive arthritis of the peripheral 
joints. The disease is not confined with joints  but also presents with extra 
articular manifestations. Etiology includes both environmental and genetic 
factors.1 Disease progresses to physical inability and joint deformity.2 
 
 Pathogenesis involves inflammatory mediators like cytokines, growth 
factors, chemokines, adhesion molecules and matrix metalloproteinases(MMPs). 
Diagnosis and diseases severity is assessed by evaluating the joint involvement, 
estimating acute phase reactants and assessing the various serological markers. 
Rheumatoid factor(RF) and anticitrullinated protein antibodies(ACPA) are major 
serological markers of RA. Lack of sensitivity of the both serological markers in 
diagnosis and progression of the disease leads to the necessity of search of new 
biomarkers for early diagnosis and halting the disease progression. 
 
 14-3-3(eta) protein, an intracellular chaperone protein has been found to 
have correlation with MMPs and joint destruction.3 The new serological marker 
14-3-3 protein belong to a family of seven isoforms and are involved in the 
pathogenesis of joint inflammation and damage. The relationship of the new 
biomarker with the disease diagnosis and progression of the disease, makes the 
marker as an addition to existing biomarkers  for more cases identification at an 
earlier stage and preventing the disease progression and deformity. 
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 So this study has been done to establish the role of 14-3-3 protein in 
rheumatoid arthritis and establish its sensitivity and specificity and for earlier 
diagnosis and treatment 
 
EPIDEMIOLOGY 
 RA  affects  0.3 to 1.5% of the total population worldwide.3 
 Based on an indian epidemiologic survey 
6 to 7 million people of india are suffering with RA.4 
 0.5 to 3.8% prevelance in women.4  
 0.15 to 1.37% prevelance in men.4 
 Cases are mostly clustered around 4th decade of life worldwide 
 Maximum cases in indian population are found to be of age group 25-29 
comparitively younger than the western diseased population.4 
 African population shows a low prevelance.5,6 
 China population also shows a low prevelance of the disease.7 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Review of Literature   
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REVIEW OF LITERATURE 
RHEUMATOID ARTHRITIS: 
 Rheumatoid arthritis, a disease involving the joints is a type of 
inflammatory  arthritis. Has been classified under autoimmune diseases. The 
etiology of the disease is multifactorial. It includes immune cause, neuroendocrine 
and pychosocial variable.8 The relationship between the etiological variables is 
unclear. Women compared to men are the major contribution to the disease 
population . 80% of the cases fall in the age group 35 to 50.9 
 
ETIOLOGY AND PATHOGENESIS OF RHEUMATOID ARTHRITIS 
AUTOIMMUNE ROLE IN DISEASE: 
 Theories on pathogenesis of rheumatoid arthritis includes autoantibodies 
and immune complexes, T cell mediated antigen response, T cell independent 
cytokine role and tumour like behavior of the synovium have also been 
identified.10  
 
Autoantibodies identified in rheumatoid arthritis patients include 
1. Rheumatoid factor (RF) is the major autoantibody found in the diseased 
patients 
2. Autoantibodies to cartilaginous collagen have also been identified 
3. Cross reactive natural autoantibodies11 (IgM) , the role of its action is 
against either histone moieties or double stranded DNA 
 
 The autoantibodies have specific high binding property for 
Catecholestrogens (CE)modified DNA.12 Autoantibodies indicates the oxidative 
lesions in DNA. 
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 8- hydroxyl-2’deoxyguanosine(8-OHdG) levels in serum and synovial 
fluid also represents the oxidative status.12 
 
 Synovial B cells release anti collagen antibody and rheumatoid factor.  
 
 Synovial inflammation is caused by the antigen glucose-6-
phosphoisomerase related to adherence to the cartilage surfaces.  
 
 The antigen antibody complexes gets adherent to the cartilage and gets 
immobilized which is responsible for the complement fixation. 
 
RHEUMATOID FACTOR: 
 Initially rheumatoid factor along with the immune complexes was 
considered as the only reason for the development of the autoimmune rheumatoid 
arthritis. But  later was determined as RF as one of the factor that leads to the 
development of acute inflammatory synovitis. Rheumatoid factor can be 
expressed even before the development of disease and vice versa even it may be 
seronegative in clinically evident rheumatoid arthritis. The patients with 
seropositive to rheumatoid factor have more severe disease when compared with 
the patients with seronegative results. RF factor role in the pathogenesis is 
through fixation and activation of classic complement pathway. IgM and IgG RF 
are found most abundantly in the synovial tissue of diseased joints. High affinity 
RF production in the rheumatoid arthritis patients  will cause T cell activation. 
There are experimental evidences for RF role in the inflammatory process of the 
disease. 
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CARTILAGE- SPECIFIC ANTIGENS: 
 Synovial inflammation is the most important finding in the rheumatoid 
arthritis patients. The inflammatory process are produced by varied number of 
joint specific antigens. The autoimmunity will vary according to the stage of the 
disease, clinical manifestations and treatment.   
 
ROLE OF CYTOKINES IN PATHOGENESIS OF DISEASE 
 Cytokines play an important role in the inflammatory process and the 
systemic manifestations.13  Cytokines  involve in the initiation and the progression 
of the inflammatory process. The over production of cytokines causes the 
synoviocyte proliferation and release of secondary mediators which are involved 
in the recruitment of inflammatory mediators. The cascade of these reactions and 
release of factors causes the disease progression and joint destruction .14 
Inflammatory markers are directly proportional to the disease progression and 
joint destruction. 
 
The markers include  
1) C-reactive protein 
2) Vascular endothelial growth factor 
3) Synovial matrix metalloproteinase 
4) And matrix digesting enzymes15 
 
CEs AND PATHOGENESIS OF RHEUMATOID ARTHRITIS:  
 Estrogen and the metabolites of estrogen(CE) have a major role in the 
disease progression and joint destruction.12 Role of estrogen in the pathogenesis of 
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the disease has been the recent area of research. Estrogen is related to the 
development of autoimmunity and hence involves in the pathogenesis of the 
autoimmune diseases like rheumatoid arthritis.16 
 
 Estrogen and its CE metabolites are found to be risk factors for the 
development of RA disease. In RA patients, synovial fluid(SF) resulted to show 
high levels of estrogen and its hydroxylated forms like 16-OHE and 4-OHE. 15,17 
16 OHE compared to 2 OHE play an important role in rheumatoid arthritis.11 
Estrogen enhances immune response by acting as a driving force for production of 
IL -10 when present at physiological levels.   Estradiol  also enhances antibody 
production via interleukin 10.18 
 
IMMUNOGLOBINS AND RHEUMATOID ARTHRITIS: 
 Class II MHC involve in the cellular immune responses in RA. Deficient 
galactosylation of the immunoglobulin is one of the reasons of autoimmune 
diseases like RA. There are evidence of defective galactosylation of 
immunoglobulin even before the onset of the disease. The defective 
galactosylation is found to be prominent on the IgG1 , IgG2 and IgG4 isotypes of 
RF19. The etiology involved in the role of defective galactosylation would be 
reduced galactosyl transferase activity in the RA B cells. Deficient galactosylation 
can be an early indicator or marker for the patients with early synovitis who 
develops into full blown rheumatoid arthritis. Autoantibodies lacking 
galctosylation are more pathogenic than with normal galactosylation in the 
pathogenesis of rheumatoid arthritis20. 
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HLA-DR ASSOCIATION IN DISEASE : 
 The genetic basis of the rheumatoid arthritis with HLA-DR was determined 
in 1970. The study of MHC using complementary DNA probes against specific 
regions of DC loci revealed the predisposition of DR to the development of the 
disease1. The susceptibility of the disease is related to the DR chains- third 
hypervariable region(from 70 thro 74 amino acids)21. The epitope found in DR4 
and DR14 related with the disease is the sequence-glutamine-leucine-arginine-
alanine (QKRAA).  
 
Old Nomenclature 
(HLA-DRB1 alleles) New nomenclature 
Association with 
Rheumatoid arthritis 
HLA-DR1 0101 + 
HLA-DR4 (Dw4) 0401 + 
HLA-DR4 (DW14) 0404/0408 + 
HLA-DRw14(Dw16) 1402 + 
HLA-DR4(Dw10) 0402 - 
HLA-DR2 1501,1502,1601,1602 - 
HLA-DR3 0301,0302 - 
HLA-DR5 1101-1104,1201,1202 - 
HLA-DR7 0701,0702 - 
HLA-DRw8 0801,0803 - 
HLA-DR9 0901 - 
HLA-DRw10 1001 - 
HLA-DRw13 1301-1304 - 
HLA-DRw14 1401 - 
 
 From Weyand CM, hicok KC,Conn DL, Goronzy JJ: the influence of 
HLA-DRB1 genes on disese severity in rheumatoid arthritis. Ann Intern med 
117:801,1992 
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CYTOKINE POLYMORPHISMS AND OTHER GENETIC 
ASSOCIATIONS: 
 Tumour necrosis factor-(TNF-) have been identified as the major 
cytokine factor involved in the pathogenesis of the disease. TNF genes are located 
on MHC locus on chromosome 6. TNF polymorphism and disease have been 
reported. Polymorphorphism of TNF- promoter region leads to altered gene 
transcription . For example polymorphism at positions -238 and -308. 
Microsatellite polymorphism of other cytokines and inflammatory mediators like 
interleukin-1(IL1),CCR5 and RANTES are also associated with the susceptibility 
of the disease22. The genetic basis of polymorphism other than MHC plays a 
minor role in the influence of the development of the arthritis but a combination 
of factors may lead to the course of disease. 
 
ENVIRONMENTAL INFLUENCES ON DISEASE: 
 No specific individual exposure have been determined as a pivotal agent 
for the development of the disease. Case controlled and restrospective studies has 
been done to determine the influence of oral contraceptives in disease. Some data 
shows a temporary protective effect. The protective effect is a delaying factor not 
a disease preventing factor. Other endocrine factors related to disease are 
corticotrophin releasing hormone and estrogen synthase. Nulliparity has been 
determined as a risk factor for the disease. But the evidence has been controversial 
by other studies. Smoking is also a risk factor for rheumatoid arthritis. 
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SYNOVIAL INVOLVEMENT WITH THE DISEASE: 
 The primary target for the rheumatoid arthritis is the synovium. The 
disease is characterized by 
1. Infiltration of the synovium with mononuclear cells 
2. Synovial intimal lining hyperplasia 
 
 Synovial intimal lining is a thin interface between synovial fluid space and 
the synovium and is devoid of  tight junctions and a definite basement membrane. 
There is increase in the cell number in RA. Two types of  cells are present in the 
lining 
1) Type A synoviocyte- macrophage like cell  
2) Type B synoviocyte- fibroblast like cell 
 
 Both the type of cells increase in RA. Type A cells increase more in RA. 
Synovial macrophage do not divide in the joint and the accumulation of cells is 
likely to ingress new bone marrow derived precursors. 
 
PROTEASES IN RHEUMATOID ARTHRITIS: 
 The progression of the disease leads to bone and cartilage destruction.  The 
process involves increased activity of proteases like matrix metalloproteases 
(MMPs) and papain like cysteine proteases. 
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MATRIX METALLOPROTEINASES(MMPs): 
Matrix metalloproteinases have been subdivided into 5 categories 
1. Collagenases includes MMP-1, -8 and -13  
2. Includes type I ,II and III- degrades interstitial collagens, MMP-2 and 9 
which are gelatinases , type IV collagen  
3. Includes MMP-3,-10 and 11- degrades non collagen matrix proteins 
4. Includes MMP-14, -15, -16, -17 , -24 and -25 which are of Membrane type  
5. MMP-7, -11, -12, -20 and -23. 
 
Collagen degradation: 
 The expression of MMP s are very low in a normal joint tissue. Their 
levels are increased in arthritic joints. The collagenase activity of MMP will 
cleave the collagen.  MMP s have specificity over collagen types like MMP -13 
cleaves type II collagen, MMP-1 cleaves type I collagen and MMP-8 are effective 
over collagen type I. 
 
Degradation of non collagenous components: 
 Mediated by stromelysins and matrilysins. Stromelysins degrade 
fibronectin, elastin, laminin and aggrecan. MMP-3 which is classified  under 
stromelysin -1 are identified to be responsible for (i) proteoglycan loss23 and (ii) 
activation of proMMP-124. 
 
 Matrilysin cleave proteoglycans which are induced by TNF- and IL-1. 
MMP s  that leaves the proteoglycans cleave the aggregan core protein at Asn341-
Phe342 bond25,26. 
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Membrane type MMPs role in RA: 
 MT1 and MT3-MMP play a role in the pathogenesis of  RA disease. 
Among both MT1 plays a dominant role. The pathogenesis in destruction is both 
of direct and indirect effects. During the disease progression in rheumatoid 
arthritis fibroblasts and osteoclast like cells will express MT1-MMP which will 
mediate bone resorption27. MMP s destroy collagenous , non collagenous matrix 
molecules and diturb the joint integrity and function. 
 
Gene expression of MMP: 
 Synthesis of MMP is regulated at the level of gene expression28. In arthritis 
varied from the low expression of MMP-2 and MT1-MMP in normal tissues,  the 
expression of these metalloproteinases are increased and constitutively 
expressed(promoters of these genes do not contain a TATA box)29. 
 
 The MMP- 1, -3 and -9  and -13  expression are regulated through 
induction by IL-1 and TNF- alpha.  Induction factors regulate the MMP gene 
expression through signal transduction pathways such as mitogen- activated 
protein kinases(MAPKs)30. 
 
CYSTEINE PROTEASES: 
 Cathepsins are classified under cysteine proteases. Cathepsins act on 
collagenases type II, IX and XI. They are regulated by cytokines and proto- 
oncogenes. Cathepsin K has been found to be involved in degradation of collagen 
type I. 
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AGGRECANASES: 
 Aggrecan is classified under proteoglycan. It is involved in compressibility 
activity on the joints due to its large size and negative charge and containing large 
amounts of water.  Two sites are susceptible for cleavage in aggrecan . one site is 
attacked by MMPs and the other site is attacked by aggrecanases.  
 
BLOOD VESSELS IN ARTHRITIS: 
 Blood vessels are the route of red blood cells and leukocytes to the 
inflammatory site. Vessels involve in cell specificity to the tissue site and 
involved in tissue growth and nutrition. 
 
NEW VESSELS IN RHEUMATOID ARTHRITIS: 
Synovitis in rheumatoid arthritis resembles tumor and wound healing process.  
Stimulus and factors involved in new vessel formation: 
(i) Hypoxia which is a major contributory towards the new vessel 
formation in RA joint 
(ii) Vascular endothelial growth factor(VEGF) – high levels are correlated 
with later joint manifestations such as degradation31. 
 
VEGF  is involved in increased levels of collagenases which is involved 
in degradation of the extracellular matrix32. 
(iii) pro inflammatory factors like IL-8,FGF and TNF- are angiogenic. 
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CARTILAGE DESTRUCTION IN RHEUMATOID ARTHRITIS: 
 Normal cartilage: it is a type of hyaline cartilage. It is avascular. The major 
components of the cartilage includes type II collagen and aggrecan. Deficiency or 
any gene alterations of majority of collagen leads to diseases such as premature 
osteoarthritis. Mutations in type II collagen leads to chondrodysplasias 
 
 Pathogenesis in Destruction of cartilage in Rheumatoid arthritis involves 
two process named enzymatic and mechanical. 
 
Enzymatic process is mediated by factors such as IL-1 and TNF-. 
Proteoglycans depletion - due to catabolic effect of IL-1, MMPs and 
aggrecanases. 
 
                                 Weakening and destruction of the cartilage 
 
 Depletion of proteoglycans in the rheumatoid arthritis leads to mechanical 
destruction of the cartilage. Streptomelysin and collagenases mRNA are increased 
in rheumatoid arthritis joints cartilage. Rate limiting step in the cartilage 
destruction is the cleavage  of the collagen. MMP s released in case of rheumatoid 
arthritis leads to the digestion of the matrix proteins. Other enzymes such as 
cathepsins are involved in the non collagenous matrix proteins. Elastase, plasmin 
and aggrecanases also contribute a major role in the cartilage destruction. 
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BALANCE OF MMPs AND TIMPs IN THE DEVELOPMENT OF 
DISEASE: 
 Tissue inhibitor of metallo proteinases(TIMP) bind to the MMPs in the 
ratio 1:1. The binding is specific to active MMPs. There are also different forms 
of TIMPs as TIMP-2 which will bind to the inactive progelatinase(MMP-2).  The 
number of TIMPs in the diseased synovial fluid is found in excess  and they form 
complexes with active collagenases. The levels of MMP:TIMP are higher in 
rheumatoid arthritis when compared with the osteoarthritis(OA). The balance 
between the culprits MMPs and the inhibitors TIMPs decides the fate of the 
disease that is the destruction of the extracellular matrix. This balance has been 
utilized in treatment purpose.  
 
ANOTHER CHECKPOINT OF BONE DESTRUCTION- RANKL: 
 Osteoclasts have been identified to be the causative for the bone 
degradation in the diseased conditions like rheumatoid arthritis. Recent studies 
have proved that the relation between the receptor activator of NFkB ligand 
(RANKL) and bone resorption modulates the activity of the disease33. The 
osteoclast development and activation mechanisms depends on RANKL.  The 
osteoclast precursors have expression of RANKL receptors known as RANK. 
When osteoclasts have expression of RANKL on their surfaces the disease 
progression to destruction of the joints happens through MMPs and cathepsin K. 
osteoprotegerin(OPG) is competes with the binding of RANKL with receptor 
RANK. The determination of RANK, RANKL and OPG from the  diseased 
synovial fluid can be done to access the bone destruction. The number of RANKL 
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compared to OPG outnumbers in RA whereas in other diseases  like OA and gout 
the difference in number is not that significant34.  Osteoclasts expressing TRAP- 
tartrate- resistant acid phosphatase have been also expressed by the synovial fluid 
of  rheumatoid arthritis35.  
 
14-3-3 ETA PROTEIN IN THE PATHOGENESIS OF RHEUMATOID 
ARTHRITIS: 
 
14-3-3 ETA PROTEIN: 
 
 
 
Courtesy : https://goo.gl/images/ttvJqZ. 
 
 14-3-3  protein is basically a chaperone protein. It belongs to a family of  
seven isoforms named as (i) beta (ii) gamma (iii) epsilon (iv) eta (v) tau (vi) zeta 
(vii) sigma. The 14-3-3 eta protein weighs 20 kDa36.  The seven isoforms share 
amino acid homology partly.  
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Structure of the 14-3-3 family chaperones: 
(i) Consists of 9 alpha helices 
(ii) The amino terminal and carboxy terminal of the isoforms vary from each 
other Functions of these chaperone proteins: 
 
 The 14-3-3 proteins form a grove which is termed as amphipathic groove. 
The grove is formed by dimerization through  N terminals of the proteins the 
dimerization can be either homo dimerization or heterodimerisation. Through the 
groove the chaperone protein interact with various proteins to carry out various 
functions like synthesis of protein, signal transduction processes, protein 
trafficking  and cytoskeletal transport37.  The signal transduction processes of  
14-3-3 proteins are recently identified to be ones involving tryptophan, protein 
kinase C(PKC) and tyrosine kinase38. 
 
ROLE OF 14-3-3 ETA PROTEIN IN RHEUMATOID ARTHRITIS: 
 Among the seven isoforms it has been identified as only eta variant have 
been in higher number in the rheumatoid arthritis. And it has been documented 
that the levels of 14-3-3 eta protein in the synovial fluid is to of very much higher 
compared with the sera of the patients. 
 
Release of the proteins in diseased condition:  
 Externalization of the protein in the diseased joints is by exocytosis 
reaction and release from the microvesicles39.  14-3-3 eta protein in the diseased 
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conditions when released to the extra cellular space acts as an inducer of various 
cells of the innate immunity system.  
Signaling pathway of 14-3-3 eta protein: 
 Cell signaling studies were carried out to understand the mechanism of 
action of the proteins extra cellularly during inflammatory conditions. 
Inflammatory signals like interleukins and tumor necrosis factors activate 14-3-3 
eta protein which act through various signaling pathways. Mainly acts through 
MAPK signaling pathway. Acts through transcription factor AP-1. Causes 
phosphorylation of ERK and JNK/SAPK in the cells which are stimulated by 14-
3-3 proteins. The activation of cells by 14-3-3 proteins differs from activation by 
TNF- as 14-3-3 does not phosphorylate p38MAPK 
 
Phosphorylation of ERK and JNK/SAPK 
 
Direct or indirect activation of transcription factor c-JUN 
 
Association of c-JUN with c-fos 
 
Formation of AP-1 transcription complex 
 
Switching on genes containing the AP -1 binding site 
 
Activation of inflammation through factors like IL-6 
 
Bone destruction through activation of MMP and RANKL 
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PATHOGENESIS OF 14-3-3 ETA PROTEIN IN DISEASE  
INVOLVES IN THE FOLLOWING PATHWAY 
 
Courtesy : https://goo.gl/images/eyoL53 
 
Courtesy : https://goo.gl/images/1Jd4CY 
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The inflammatory mediators or factors involved in the pathogenesis and the 
progression of the disease through 14-3-3 are  
(i) MMP-1 
(ii) MMP-9 
(iii) RANKL 
(iv) TNF 
(v) IL-6 
(vi) IL-1 
 
(i) MMP 1: matrix metalloproteinase 1  (MMP-1) is classified under one class 
along with MMP-8 and 13. MMP-1 has collagenases activity.  Their 
activity is increased in the arthritic joints. The expression of MMP-1 is 
regulated through IL-1 and TNF. The levels of MMP will correlate with 
levels of 14-3-3 eta protein levels in the synovial fluid. 
(ii) MMP-9: matrix metalloproteinases 9(MMP-9)   is classified under 
category 2 along with  MMP-2. MMP-9 is a gelatinase which causes 
degradation of  collagen type IV. MMP-9 is determined to be major factor 
responsible for the joint destruction.   
(iii) RANK-L:  the osteoclasts cells have receptors for RANKL . osteoclast 
causes bone destruction. The expression of RANKL is increased in RA 
causing increased bone degradation. Thus the expression of RANKL is 
involved in the pathogenesis of the bone degradation and severity of the 
disease.       
(iv) TNF: it’s a pleotropic cytokine. The functions of TNF-  includes 
cytokine production enhancement, adhesion molecule production and 
proliferation of MMP.  
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(v) IL-6: cytokine  like IL-6 is involved in the initiation and the progression of 
the inflammatory process. Causes synoviocyte cell recruitment and release 
of inflammatory factors leading to progression of the disease  
(vi) IL-1: cytokines like Il-1 is also involved in the cell recruitment and 
inflammatory process. Causes the release of matrix metallo-proteinases 
which are responsible for the joint destruction. 
 
Significance of 14-3-3 protein levels in other diseases: 
Carcinoma40: 
 14-3-3 epsilon protein has been used in the prognosis and severity of 
hepatocellular carcinoma. 
 
Creutzfeld-jacob disease41: 
 14-3-3 protein levels in CSF has  been significant in the diagnosis of 
cretzfeld Jacob disease with a sensitivity of 94% and specificity of 84%. 
 
Alzheimer’s disease42:  
 14-3-3 a regulatory protein has been studied to be found in higher levels in 
the CSF of persons suffering from alzheimer’s disease 
 
Multiple sclerosis43: 
 14-3-3 eta protein is used in the multiple sclerosis as a marker for axonal 
pathology and the disease progression 
 
Infarction44: 
 Specific isoforms of 14-3-3 proteins has been identified in the neuronal 
cells . these proteins have been produced as a reaction to ischemic stress. It may 
be a protective mechanism for the survival for the cells against death. 
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And HIV45: 
 It has been studied that 14-3-3 protein has been demonstrated in CSF of 
patients suffering from HIV associated dementia complex (HADC). The disease 
has features of encephalitis, leucoencephalopathy , astrogliosis and neuronal loss. 
 
 Risk factors in the development of rheumatoid arthritis: 
 
ANTICYCLIC CITRULLINATED PEPTIDE ANTIBODIES: 
 RF was considered to be major contributory factor towards the diagnosis of 
the disease. But RF has also been positive in the sera of other diseases like 
systemic lupus erythematosus(SLE), Sjogren’s syndrome, viral infections like 
mononucleosis, hepatitis, influenza, parasitc infections like trypanosomiasis etc, 
chronic bacterial infections and other hyperglobulinemic status. 
 
 Arginine undergoes deamination produces citrulline. The antibodies 
against citrulline termed as ACCP  are found to present in the sera of rheumatoid 
arthritis patients. Recombinant fillagrin have been developed to identify these 
autoantibodies ACCP in sera of the patients. 
 
TWINS- A RISK FACTOR : 
 There is eight fold increase in the risk of developing rheumatoid arthritis if 
it is a monozygotic twin46,47. The risk factor in the twins is due to the 
polymorphism of HLA-DRB chains.  
 
SEX AND THE DISEASE: 
 Women are more susceptible for development of disease when compared 
to men. The reason for female preponderance is estrogen which has a stimulatory 
effect over the immune system causing the development of autoimmune 
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rheumatoid arthritis. There are studies proving oral contraceptives are protective48 
against severity of diseases and also studies to prove women with one child are 
less susceptible for the disease. It has been proved that patients improve during 
pregnancy. Whereas multiparity is a risk factor for the development of the disease. 
Smoking women are at high risk to develop rheumatoid arthritis and to be 
seropositive when compared to the non smoking women. The reason for increased 
severity in smoking individuals is due to the glutathione S transferase M1- null 
polymorphism. 
 
GOUT AND RA A NEGATIVE CORRELATION: 
 There is an association between seronegative RA and gout. With increased 
levels of uric acid in patients with rheumatoid arthritis there has been a decrease 
in the severity or improvement in the disease activity49. A hypothesis has been 
proposed that hyperuricemia is a state of anti- inflammatory. 
 
DIET: 
 No strong evidence of diet playing a role in the relation to the disease 
development or any progression. 
 
ATOPY AND RA: 
 In some sub populations it has been demonstrated that when there is an 
increase in the evidence of development of atopy there is a decrease in the 
rheumatoid arthritis incidence50. 
 
EARLY RHEUMATOID ARTHRITIS: 
The pattern of onset varies from individual to individual. 
Insidious onset: 
 55%-65% cases have insidious onset51. 
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Symptoms and signs includes 
(i) Systemic symptoms 
(ii) Articular symptoms 
(iii) Nonspecific symptoms like fatique, malaise, puffy hands or diffuse 
musculoskeletal pain 
(iv) Asymmetrical presentations leading to later symmetrical presentation 
(v) Symmetrical involvement is due to bilateral release of neuropeptides 
(vi) Morning stiffness due to fluid accumulation during sleep in the 
inflamed tissue. 
(vii) Muscle atropy around the affected joint 
(viii) Weakness due to pain 
(ix) Low grade fever- rare presentation 
(x) Weight loss due to catabolic cytokines 
 
Acute or intermediate onset: 
 8-15% of patients develop symptoms acutely or intermediate. Patient will 
describe sudden onset of symptoms and then pain develops to other joints. 
Diagnosis will be difficult and may be confused with vasculitis or sepsis. Acute 
onset may be presented with fever. 
 
Joint presentation in disease: 
 First involvement is the small joints when compared to larger joints. 
 The joints involved are metacarpophalangeal joints(MCP), proximal 
interphalangeal joints(PIP), metatarsophalangeal joints(MTP) and wrists52. Larger 
joints present later after the small joints. Present as synovitis or systemic 
presentations 
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JOINT INVOLVEMENT MEAN % OF PATIENTS 
RANGE OF % OF 
PATIENTS 
MCP, PIP 91 74-100 
WRISTS 78 54-82 
KNEES 64 41-94 
SHOULDERS 65 33-75 
ANKLES 50 10-67 
FEET 43 15-73 
ELBOWS 38 13-60 
HIPS 17 0-40 
TEMPEROMANDIBULAR 8 0-28 
SPINE 4 0-11 
STERNOCLAVICULAR 2 0-6 
PARA-ARTICULAR 
SITES 27 20-29 
 
 Modified from Guerne P-A, Weisman MH: Palindromic rheumatism: part 
of or apart from the spectrum of rheumatoid arthritis. Am J Med 16:451-460, 
1992. Copyright 1992, with permission from Excerpta Medica, Inc. 
 
Other patterns of disease: 
Adult onset Still’s disease: 
 Adult onset Still’s disease present with an unusual presentation with fever 
as early and predominant symptom. The seromarkers(RF and antinuclear 
antibodies) will be negative in the case of Still’s disease53. There is no sex 
indifference in the presentation of Still’s disease. 
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 Fever will be the only presentation before arthritis making the diagnosis 
difficult. At times salmon- coloured or pink macules present in the trunk or 
extremities. There is cervical spine involvement and neck motion will be lost. The 
diagnosis may be more confusing with presentation with pleural effusion, 
pericarditis and abnormal liver function test.  There will unusual elevation of 
ferritin levels. Adult onset Still’s disease have been a diagnosis by exclusion so 
far. 
 
CRITERIA FOR DIGNOSIS OF STILL’S DISEASE: 
MAJOR CRITERIA MINOR CRITERIA 
Temperature >39oC for >1 week Sore throat 
Leukocytosis >10,000/mm3 with >80% 
PMNs Lymph node enlargement 
Typical rash Splenomegaly 
Arthralgias>2 week Liver dysfunction (high AST/ALT) 
 Negative ANA, RF 
 
 Diagnosis is based on if more than 2 major criteria are present. Prognosis 
of Still’s disease is good when the systemic presentation are more when compared 
to articular presentation. Treatment includes aspirin or nonsteroidal inflammatory 
drugs (NSAIDs), oral glucocorticoids and methotrexate.  
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Palindromic pattern of onset: 
 Starts with pain in one joint and and worsens by time and later present with 
swelling and erythema. They resolve in reserve sequence. The palindromic 
disease develops to rheumatoid arthritis in most of cases who have HLA-DR454. 
Some of the individuals develop rheumatoid arthritis from palindromic disease. 
Some palindromic cases resolve completely without development of disease. The 
development of palindromic disease to rheumatoid arthritis show seropositive 
rheumatic factor and CCP positive in later stage after the evident RA. 
 
Effect of age in the onset of the disease : 
 RA developing in older age presents with stiffness and swelling of joints. 
Patients presenting at an earlier age may be presented with subcutaneous nodules 
or RF. 
 
Unusual presentation along with other diseases: 
 RA may be presented along with other diseases like poliomyelitis, 
meningioma, encephalitis, cerebral palsy, strokes, neurovascular syphilitic. Joints 
in the paralyzed side are spared.  
 
Arthritis robustus: 
 This is the unusual reaction of the patients to the disease55. Causes 
proliferative synovitis with little pain and disability. Also present with 
periarticular osteopenia, new bone formation and subcutaneous nodules.  
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JOINT INVOLVEMENT IN THE DISEASE: 
CERVICAL SPINE: 
 Causes osteochondral destruction. Radiographic picture shows lateral 
narrowing of the spine. Characterized by pain. Passive motion may be positive in 
the diseased spine.  The mechanism includes extension of inflammatory process 
from adjacent neurocentral joints and cervical instability. 
 
The atlantoaxial joint may lead to subluxation. Subluxation can occur 
(i) Anteriorly 
(ii) Posteriorly 
(iii) Vertically 
 
Clinical symptoms include 
 Spastic quadriparesis with sensory loss  
 Medullary dysfunction with vertebral artery compression  
 Paresthesias in shoulders or arms 
 Symptoms of spinal cord compression includes 
 Drop attacks 
 Sphincter control is lost 
 Level of consciousness is altered 
 Sensation of head falling forward 
 Dysphagia, dysarthria vertigo 
 Hemiplegia, nystagmus 
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THORACIC, LUMBAR AND SACRAL SPINE: 
 Thoracic, lumbar and sacral spine are not involved in the rheumatoid 
arthritis. Apophyseal joints are not involved. Synovial cysts may cause 
compression over the spine causing neurological pain and deficits. 
 
TEMPEROMANDIBULAR JOINT: 
 Commonly involved joint in the rheumatoid arthritis is temporomandibular 
joint. Radiograph will produce bone alterations such as mandibular condyle and 
eminentia articularis are eroded.  
 
Physical examination: tenderness and auscultation for crepitus 
Symptoms: acute pain, not able to close mouth 
Radiologic finding: erosion  and cysts of the mandibular cyst 
 
CRYCOARYTENOID JOINTS: 
 Crycoarytenoid joint is involved in rotation of the vocal cords and plays a 
role in the pitch and tone of the voice. 
 
 The involvement of the joint in rheumatoid arthritis produces hoarseness of 
the voice in rheumatoid arthritis vocal cords are adducted to midline causing 
stridor ocassionally will cause aspiration of pharyngeal contents 
 
 It has been studied that about 50% of patients with rheumatoid arthritis 
have involvement of this joint.  
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EAR OSSICLES: 
 Rheumatoid arthritis patients complain of hard of hearing. This has been 
postulated to the salicylate toxicity. Causes conductive type of hearing loss. The 
rheumatoid ears are due to erosions and shortening of the ossicles produced by 
erosive synovitis 
 
STERNOCLAVICULAR AND MANUBRIOSTERNAL JOINTS: 
 The synovium and the cartilaginous disc of both the joints  are involved in 
the rheumatoid arthritis.  
 
 Symptoms: pain over the joints while lying on the sides 
 Radiograph: shows delineation of sternoclavicular joint 
 
SHOULDER: 
 The shoulder synovium and clavicle- particularly distal third is involved in 
the rheumatoid arthritis.  Rotator cuff and the muscles of the neck and chest are 
also involved. The rotaor cuff involvement is the principle reason for the 
symptoms  
 
 Symptoms: pain and inflammation. Decreased range of motion. obstruction 
to venous return from the arm. 
 
 Radiographic finding: superior subluxation, rotator cuff tears, proliferative 
synovitis, erosions, irregular capsular attachment, adhesive capsulitis, soft tissue 
swelling, subacromial bursitis and glenohumeral joint effusions56. 
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ELBOW 
 Stable Hinge type of joint 
 Involvement is about 20 -65% 
 Symptom: may lead to loss of full extension. Shoulder and wrist movement 
will compensate the loss of slow motion. 
 
HAND AND WRIST: 
 Both the joints involve as a functional unit. 
 Extensor carpi ulnaris muscle is weakened which causes radial deviation of 
the wrist and carpal bone respond differently.  
           Proximal row shows ulnar deviation 
           Distal row shows radial deviation 
 
 It is not mandatory that only when there is erosion of the bones it leads to 
deformity.  Even without erosions of the bone patients present with deformity.  
 
 Wrist with Dorsal swelling many a times present as a early sign in the 
rheumatoid arthritis57. 
 
Synovial proliferation inside the wrist 
 
Pressure increases 
 
Tendons, ligaments and articular disk are destroyed 
 
Communications between radius, ulnar and carpal bones are lost 
 
Ulnar bones shows a dorsal prominence 
 
31 
 
 
Patients present with carpal tunnel syndrome mostly bilaterally. 
Disease progression leads to (i) loss of joint space 
                                                (ii)  ankylosis 
carpal to metacarpal ratio(C/MC)(length of carpus/ length of third metacarpal) is 
used as powerful indicator about bone deformity and useful for corrective 
measures58 
 
MRI: detects early synovial proliferation and bone erosions 
Clinical tests for hand involvement: grip test 
 
Deformities: 
 SWAN NECK DEFORMITY:  due to shortening of interosseous muscles and 
intrinsic muscles 
  (i) flexion of DIP and MCP joints 
  (ii) hyperextension of the PIP joint 
 if accompanied with OA shows marginal erosion also  
 
 BOUTONNIERE DEFORMITY: 
 During the course of the disease chronic inflammation of the PIP joint 
causes flexion of the joint and DIP will remain in hypeextension to produce this 
deformity. 
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Later stages of the disease produces resorptive arthropathy 
 THUMB DEFORMITIES 
1. TYPE I: MCP inflammation and stretching of joint 
2. TYPE II: CMC inflammation and volar subluxation 
3. TYPEIII: exaggerated adduction of 1st metacarpal bone, MCP- flexion 
and DIP- hyperextension. 
 TENOSYNOVITIS 
 PAINFUL LOCK OF FINGER: 
 
Due to nodules or fibrin deposits in the tendon sheats. 
HIP: 
 Less frequently involved joint in RA. 
 Symptoms:  Complaints of pain the groin and lower buttock 
                     Pain in the lateral aspect of hip 
 
 Radiographic finding: femoral head – collapse and resorption 
 
Acetabulum remodeling and medial displacement - protrusio acetabuli 
Femoral head may present with cystic lesions which will decrease joint space. 
 
KNEES: 
 Early disease: quadriceps atrophy leading to loss of full extension. In later 
course of the disease presents as fixed flexion contracture 
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 Persons who varum or valgum deformity when developing rheumatoid 
arthritis whose pressure on medial side will be more present with 
radiographic feature of erosion and thinning of cartilage 
 
BAKER’S CYST: 
 Also known as popliteal cyst. Caused due to the large effusion causing 
increase in the pressure59. This may lead to the protrusion of posterior contents 
into the joint causing the bakers cyst. 
 
The fluid entering the cyst will be of one way valve will not return60 back 
to the posterior compartment which leads to increasing pressure in the cyst. 
Jayson and Dixon have demonstrated this one way communication of the cyst. 
The very high pressure in the popliteal space leads to the rupture of contents down 
to calf or rarely ruptures superiorly into the posterior thigh. Rupture can also 
occur posteriorly in the space between the medial head of gastrocnemius and 
biceps tendon insertion.  
 
 Clinical symptoms: intact cyst will cause compression on the superficial 
veins  presented as dilatation of the veins and edema61. 
 
 Rupture of the contents to calf will present as thrombophlebitis presenting 
with swelling and tenderness. 
 
Systemic sign – leukocytosis 
Local sign- crescentic hematoma beneath the ankle malleoli62  
Diagnosis is by invasive arthrography 
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Invasive procedures can be avoided using ultrasonography and MRI 
 
ANKLE AND FOOT: 
 Ankle and foot will not be affected in mild cases of rheumatoid arthritis. 
The severity of the disease causes the involvement of ankle and foot.  
 
 First sign: swelling anterior and posterior to the malleoli. 
 
 Due to inflammatory and proliferative process in the disease causes 
loosening of connections between the ankle, fibula and tibia. The progression of 
the joint involvement causes pronation deformity and eversion of the foot. 
Patients of RA ( one third of them) develop disease of feet.  
 
 Achilles tendon: rheumatoid nodules63 develop in this tendon which will 
undergo rupture spontaneously. 
 
 Rocker bottom deformity: develops due to  progressive eversion of the 
subtalar joint and pain which leads to lateral subluxation. Subtalar joint is the one 
which controls the eversion and inversion of the talus. Patients will complain of 
walking difficulty over the uneven surface because of tis eversion deformity. 
 
 Cock-up deformity: MTP joints are involved in the RA disease 
significantly which in due course leads to downward subluxation of metatarsal 
heads leads to cock-up deformity of the PIP joints. The subluxation can cause 
pressure necrosis of the plantar surfaces and may develop ulceration over PIP 
joints. 
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DIP joints are rarely involved in RA. 
Another cause of foot pain is tarsal tunnel syndrome. 
 
The disease progression in the foot are as follows64 
 Inflammation of the intermetatarsal joints 
 Extend to the forefoot 
 The fatty cushion of the plantar surface will extend anteriorly 
 Subluxation of the toes 
 Subluxation of the metatarsal heads 
 Hallux valgus and stacking of toes 
 
 DIP joints are rarely involved in RA. Rigid hallux caused in RA will  be 
very painful and may require surgical intervention65 
 
 Some patients with RA foot involvement may develop tarsal tunnel 
syndrome. Radiograph shows erosions in the foot in such patients. 
 
EXTRA- ARTICULAR MANIFESTATIONS OF RHEUMATOID ARTHRITIS: 
 These manifestations depends on the duration and severity of the disease. 
These reason behind these extra-articular manifestations is the extra-articular foci 
of an immune response66. These extra articular manifestations are related with 
increased risk of mortality67 
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SKELETON: 
 Skeleton has a cortical and trabecular part. These parts will respond to the 
diseases differently. Postmenopausal women should be treated earlier and 
aggressively as they would be presented with overlapping osteoporosis. Bone loss 
may be secondary to glucocorticoid therapy.The synovial penetration cause cyst 
formation which will weaken the bone which is also predisposing to fracture. 
Adequate treatment in both RA and also osteoposrosis prevents bone loss68. Bone 
loss due to glucocorticoid therapy is of two phases. First phase involves rapid 
bone loss followed by chronic slower rate of bone loss69. And the bone loss due to 
the glucocorticoid therapy can be reversed70. The bone loss in RA leads to stress 
fractures common in the site of bone loss71. 
 
MUSCLE: 
 Muscle weakness is a common feature od RA . the weakness may be due to 
inflammation or may be a response to pain. Rarely present with muscle 
tenderness. 
 
 Nodular myositis: lymphocytes and plasma cells are accumulated leading 
to degeneration of the muscle fibers. 
 
5 stages72 of muscle disease in RA 
1. Muscle bulk is decreased leading to atrophy 
2. Peripheral neuropathy 
3. Steroid myopathy 
4. Myositis and muscle necrosis 
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5. Dystrophic process and end stage of inflammatory myositis 
 
Biopsy: shows atrophy of type II fibers 
              Active myositis  and focal necrosis will be seen 
 
Also shows disproportionately high ESR 
Lymphocytes in the biopsied muscle synthesize immunoglobulin M AND RF 
Myositis will appear as patchy nodules. The nodules are comprised of plasma 
cella as well as lymphocytes. 
 
SKIN: 
 Rheumatoid nodules is the most frequent skin manifestation.  
 Skin over the synovitis becomes thin and atrophic. 
 Palmar erythema is another skin manifestation seen in RA 
 Vasculitis features 
 Livido reticularis- discoloration seen in the extremities 
 Associated with antiphospholipid antibodies in the circulation73 
 
EYE: 
 Eye manifestations are seen in the complicated RA. The rheumatoid 
process produces scleritis and episcleritis. Both occurs less than 1% RA patients74.  
The connective tissue of eye is highly differentiated and forms aggressive form of 
disease when it is involved. Will not produce discharge but cause tearing 
response. May cause visual loss. Scleritis  may be superficial or generalized. 
Extension into the uveal layer causes scleromalacia perforans. Perilimbic ischemic 
ulcers produced by RF-IgG complexes. If these ulcers are left untreated it leads to 
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perforation of the anterior chamber. Can also produce chronic blepharitis in RA 
eye in the individuals who have keratoconjunctivitis sicca secondary to Sjogren’s 
syndrome. 
 
RHEUMATOID NODULES: 
 Nodule has a centre of necrosis surrounded by fibroblasts and 
inflammatory cells. Nodules have a tendency to grow and encroach the connective 
tissue matrix. The earliest nodules to be identified is to be of size 4mm75. The 
nodules increase in size by enchroaching the adjacent cells and form necrosis 
which is intiated by vasculopathy and protein destruction by connective tissue 
matrix. Most of rheumatoid nodules are present on the extensor surface. Eg: 
olecranon process of ulna. 
 
 Characteristic of nodules:  they are subcutaneous, consistency vary from 
soft to hard and attached firmly to the periosteum. 
 
 Contents of the nodules: macrophage and nonsynoviocyte fibroblasts. 
Other sites of nodules: 
 Sacral nodules 
 Occipital nodules 
 Nodules in the larynx 
 Nodules in the heart and lungs 
 Nodules on the sclera 
 Nodules in the vertebral bodies. 
 Nodules in central nervous system(CNS) 
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Nodules in the sacrum are mis interpreted as bed sores. 
Nodules in the sclera may go for perforation. 
Nodules in the CNS involves mostly leptomeninges76 
Development of nodules: mediated through immunological reactions. Cytokines 
mediate the reaction. 
Initial nodule development is through the affected arterioles which leads to 
complement activation  
Rheumatoid nodulosis77: positive RF with episodes of intermittent synovitis and 
cystic lesions of small bones of hands and feet. 
The nodules enveloping cells have the cabability to c[produse collagenase and 
protease which lead to the disease activity78. 
 
DIFFERNTIAL DIAGNOSIS OF RHEUMATOID NODULES 
1. Benign nodules: non tender and present in non RA individuals 
2. Granuloma annulare: intracutaneous, slowly resolve, not associated with 
any disease 
3. Xanthomatosis: no bone involvement. Occurs in patients with high 
lipoprotein levels  
4. Tophi: occurs in gout 
5. Other conditions: like acrodermatitis chronica and leprosy.  
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FISTULA: 
 Can be sterile or septic. Forms a connection to the skin and bone. 
 
INFECTION: 
 Occurs as a complication of rheumatoid arthritis. Common sites of 
infection are pulmonary, skin infections79,80. Infections increase with increasing 
age,  with extra articular manifestations, leukopenia, chronic lung  disease, 
alcoholism, DM and glucocorticoid therapy. Pseudoseptic arthritis should be 
differentiated from infection81. 
 
The infection is worsened with the following factors 
 leukopenia 
 increasing age 
 patients with extra articular manifestations 
 associated with other diseases like chronic lung disease, diabetes mellitus, 
alcoholism and treatment with glucocorticoids. 
 DMARD is not producing increased risk of infections82,83, which makes 
DMARD safer to use than glucocorticoids. 
 Infections should be identified at an earlier stage and treated. 
 
CANCER: 
 Increased risk to developing cancer in rheumatoid arthritis patients. 
Increased risk to develop  lymphoma, interstitial fibrosis leads to lung carcinoma 
and also increased risk to develop hodgkin’s disease, non Hodgkin’s lymphoma 
and leukemia. Lung carcinoma is of bronchoalveolar type84. Interestingly RA 
patients have a decreased incidence of gastro intestinal tumors85. 
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HEMATOLOGICAL COMPLICATIONS: 
 Most patients have a tendency to develop normocytic hypochromic anemia. 
Patients may also have additional B12 or folate deficiency anemia86. 
 
Points to remember when diagnosing anemia in rheumatoid arthritis patients 
1. High ferritin levels in anemia of chronic disease like RA when compared 
with iron deficiency anemia 
2. Folate and B12 deficiency will mask iron deficiency anemia by increasing 
mean cell volume and mean cell hemoglobin levels . 
3. ESR values will correlate inversely with hemoglobin levels in RA 
4. Erythropoietin level87 will not be increased to the level such with iron 
deficiency anemia 
- Total erythroid turnover is reduced 
- red cell aplasia is a rare finding in RA 
- eosinophilia and thrombocytosis are often associated with RA88 
- a subset of RA patients have large granular lymphocytes(LGLs) 
- paraproteinemia when coexists with RA have a poor prognosis 
 
VASCULITIS: 
 Vasculitis in RA occurs due to the inflammatory change in the small blood 
vessels.  
 
 Systemic vasculitis is a dreadful complication of RA. The incidence of the 
systemic vasculitis have been decreased in these days because of the aggressive 
treatment modalities 
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 Pathology of vasculitis in RA: panarteritis , infiltered with mono nuclear 
cells, fibrinoid necrosis is seen in the active lesion,obliterative endarteritis, 
immune complexes deposits in the vessels. 
 
 When large vessels are involved the vasculitis resembles poly arteritis 
nodosa89. 
 
Clinical presentation of vasculitis 
- distal arteritis present with hemorrhage or gangrene 
- ulceration 
- peripheral neuropathy 
- pupura which is of palpable type 
- arteritis of viscera which inludes heart, kidney, liver etc 
- paresthesias or burning feet 
- weakness 
- rheumatoid pachymengitis, a rare presentation of RA involving the 
brain. 
- larger vessel involvement resembles polyarteritis nodosa 
 
Risk factors for development of vasculitis in RA90. 
 High RF value 
 Joint erosions 
 Glucocorticoid therapy 
 Cryoglobulins 
 Nodules- subcutaneous 
 males 
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RENAL COMPLICATION: 
 Rare involvement by the rheumatoid arthritis disease. It may be involved as 
a complication of treatment. Amyloidosis is a complication of RA. Renal 
papillary necrosis: caused by phenacetin use in the treatment. 
 
Salicylates and other NSAIDS also produce renal changes. 
 
Membranous neohropathy: caused by gold salts and D- pencillamine therapy 
Focal necrotizing glomerulitis: seen in patients with disseminated vasculitis 
 
PULMONARY COMPLICATION: 
Pulmonary involvement in RA may present as one of the following 
 Small airway disease 
 Pleural disease 
 Pulmonary hypertension 
 Interstitial fibrosis 
 Bronchiolitis 
 Nodular lung disease 
 
Small airway disease: 
 Diagnosed by specific pattern of pulmonary function tests. There are 
studies stating that small airway disease is not a direct complication but a 
overlapping of diseases. 
 
Pleural disease: 
 Commonly an autopsy finding. Rarely present as active disease during the 
life time. Pleuritic pain is the complaint but a rare feature. May develop effusions 
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even large enough to cause dyspnea. The rheumatoid exudative effusions on 
examination shows low glucose levels. Another low glucose level in exudative 
effusion examination is tuberculosis91  
 
Pulmonary hypertension: 
 Seen in >30 percent of RA patients92. Mostly they are silent without any 
symptoms. Diagnosed with noninvasive echocardiograms 
 
Interstitial fibrosis: 
 Caused by increased activity of mesenchymal cells to RA. Present as 
diffuse reticular or Reticulonodular pattern. Radiograph- shows honey comb 
appearance. High resolution CT- shows lattice appearance. Pathological 
examination shows diffuse fibrosis and mononuclear cell infiltrate. The functional 
defect is alveolocapillary gas exchange. Mild cases shows more lymphocytes on 
bronchoalveolar lavage. Severe cases shows neutrophils in the bronchoalveolar 
lavage. Interstitial pneumonitis will be the finding in cases of RA with coexisting 
Sjogren’s syndrome. The initial defect is diagnosed by single breath carbon 
monoxide diffusion capacities93.    
 
Bronchiolitis: 
 Rare presentation in RA. Pathologic examination shows fibrosis and 
exudates in the bronchioles and the alveoli 
 
Nodular lung disease: 
 Nodules may appear single or in groups. When presented with multiple 
nodules they have the tendency to coalesce. Diagnosis is by needle biopsy. 
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CAPLAN’S SYNDROME94:  
 Pneumoconiosis with RA. It is a rare presentation with obliterative lesion 
seen as occupational hazard in the mining individuals.  
Nodules may progress to produce cavity and complicating to fistula formation. 
Some of the rheumatoid nodules have been associated with coexisting 
bronchogenic carcinoma95. 
 
CARDIAC COMPLICATIONS: 
 May be due to granulomatous proliferation or vasculitis. 
 
 Pericarditis: there are studies showing 50% of RA patients with 
pericarditis. Echocardiogram shows pericardial effusion. There are also evidence 
of contrictive pericarditis and cardiac tamponade in rheumatoid arthritis. 
 Myocarditis: Myocarditis present as granulomatous or inflammatory 
disease. Infiltrated by mononuclear cells. Mostly would not present with any 
clinical symptoms. 
 
 Endocardial inflammation: Presents with mitral or atrial involvement. 
 
 Conduction defects: There are studies showing that 30% of patients with 
rheumatoid arthritis present with complete heart block. 
 
 Coronary arteritis: Present with vasculitis and develop myocardial 
infarction. 
 
 Granulomatous aortitis: granulomatous type of aortitis. 
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DIAGNOSIS OF RHEUMATOID ARTHRITIS: 
 Diagnosis is based on clinical examination, and evidences supporting the 
history and examination 
 
CRITERIA FOR DIAGNOSIS- REVISED AMERICAN RHEUMATISM 
ASSOCIATED CRITERIA 
1. EARLY MORNING JOINT STIFFNESS: 
 The stiffness present in morning soon after rising from bed and lasts for a 
minimum of 1 hour 
 
2. ARTHRITIS OF SMALL (HAND) JOINTS: 
 Atleast one joint is swollen in the wrist region either MCP or PIP joint 
 
3. ARTHRITIS INVOLVING THREE OR MORE JOINTS: 
 At least should present with 3 simultaneous joint involvement with soft 
tissue swelling. There are 14 possible joints including PIP,MTP, ankle, wrist, 
knee, elbow and MCP joints. 
 
4. SYMMETRIC ARTHRITIS:  
Simultaneous involvement of joints on both sides. 
5. RHEUMATOID NODULES: 
Subcutaneous nodules over the bony prominences 
6. RHEUMATOID FACTOR: 
Positivity by any standard method 
7. RADIOGRAPH FINDINGS: 
Erosions or bony calcifications apart from osteoarthritis. 
For diagnosis: - 4 out of 7 criteria should be present 
                  - clinical criteria should be present for a minimum of 6 weeks 
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IMPORTANCE OF EARLY DIAGNOSIS OF RHEUMATOID ARTHRITIS 
 The diagnosis of rheumatoid arthritis till date seams to be difficult because 
of atypical presentation of the patients. Not all the patients present with typical 
features and satisfies the scoring to be diagnosed as rheumatoid arthritis. It is 
important to diagnose earlier the disease as there are effective therapies for 
treating RA and a deformity and long term disease can be halted at an early stage. 
And also it should be considered that the non diseased patients should not treated 
with the drugs and chances of developing adverse effects. The difficulty in 
diagnosis and the necessity in the early diagnosis and treatment of RA to halt the 
disease progression, newer markers are needed to complement with the existing 
criteria for diagnosis to identify more number of cases. Thus the identification of 
newer marker 14-3-3 protein in the rheumatoid arthritis patients can compliment 
the existing diagnostic criteria.  
 
ACR criterion for sensitivity and specificity of various diagnostic criteria     
CRITERIA SENSITIVITY SPECIFICITY 
EARLY MORNING STIFFNESS 68 65 
ARTHRITIS INVOLVING MORE 
THAN 3 JOINTS 80 43 
HAND JOINT ARTHRITIS 81 46 
SYMMETRIC ARTHRITIS 77 37 
RHEUMATOID NODULES 3 100 
RHEUMATOID FACTOR 59 93 
RADIOGRAPHIC FINDINGS 22 98 
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 There are no single marker with good sensitivity and specificity. Therefore 
the diagnosis is a combination of markers and also there is need for newer 
markers for early diagnosis 
 
TREATMENT OF RHEUMATOID ARTHRITIS: 
 Show good improvement with NSAIDs. 
Glucocorticoid therapy – improve the symptoms and patients routine 
physical activity. Intramuscular methylprednisolone are practiced by some of the 
rheumatologists. But patients who are under long term glucocorticoid therapy 
develops osteoporosis in future.  
 
 Tetracycline derivatives inhibit MMP’s 
 
 Disease modification therapy: DMARDs(disease modifying anti 
rheumatoid drugs) show good improvement in the patients. 
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AIM AND OBJECTIVES OF THE STUDY 
 
 The aim of the study is to estimate the levels of 14-3-3 eta protein in the 
serum of rheumatoid arthritis patients 
 Compare the levels with rheumatoid factor positive patients and 
rheumatoid factor negative patients. 
 Compare the levels with healthy individuals 
 Establish the sensitivity and specificity of the new marker for the diagnosis 
of rheumatoid arthritis. 
 To establish its adjuvant role in the diagnosis of the disease. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials & Methods   
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MATERIALS AND METHODS 
 This is a case control study and the study was conducted after getting the 
ethical committee approval from MADRAS MEDICAL COLLEGE.  
 
 The study population includes 60 patients and 30 healthy age and sex 
matched individuals. 
 
 The patients were selected from the rheumatology outpatient department 
from the Rajiv Gandhi Government General Hospital, Chennai. The patients were 
explained about the purpose of study and consent was obtained from the 
individuals. 
 
INCLUSION CRITERIA:  
Group 1: rheumatoid factor positive patients 
Group 2: rheumatoid factor negative patients. 
Group 3: age and sex matched healthy control 
 
EXCLUSION CRITERIA:   
 Patients with active infection 
 SLE 
 Psoaritic arthritis 
 Jeuvenile arthritis 
 Spondylo arthritis 
 Diabetes mellitus 
 Hypertension 
 Other systemic diseases 
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SAMPLE COLLECTION: 
 3 ml of venous blood was collected from the patients and healthy 
individuals and was transferred to plain red tube and was allowed to clot. After 
adequate clotting, centrifuge was done to separate the serum. The serum was 
pipetted and stored in aliquots. The following investigations were carried out in 
the serum 
 
 Serum 14-3-3  - ELISA method 
 Rheumatoid Arthritis factor  - Quantitative slide agglutination method 
 CRP  - turbidimetric immunoassay 
 Serum Uric acid - Spectrophotometric method 
 ESR -  Automated 
 Complete blood count- Automated cell counter 
 
ESTIMATION OF 14-3-3 PROTEIN: 
METHOD: Enzyme linked immune sorbent  assay – non competitive sandwich 
method 
 
TEST PRINCIPLE: 
 The method is based on the biotin antibody sandwich technology. The 
ELISA plate wells will be coated with 14-3-3 eta monoclonal antibody. Then the 
serum containing 14-3-3 eta protein should be incubated. Then anti 14-3-3 
antibodies labeled with biotin united with streptavidin- HRP is added. These form 
a immune complex with antigen antibody complex. Then the unbound enzymes 
are washed after incubation process. Then substrates A and B are added. The 
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solutions in the well turn to yellow which was blue initially. The concentration of 
the colour formed is directly proportional to the concentration of the 14-3-3 eta 
protein present in the serum. 
 
REAGENTS AND MATERIALS USED: 
1. Standard solution(4000ng/L)- 0.5ml 
2. Dilution for standard preparation- 3 ml 
3. Coated ELISA plate 
4. Streptavidin-HRP 
5. Washing concentrate(30X) 
6. Anti YMHAH antibodies labelled with biotin 
7. Chromogen solution A 
8. Chromogen solution B 
9. Stop solution 
 
ASSAY PROCEDURE: 
 Standard preparation: The standard solution is diluted to various 
concentrations as follows 
2000ng/L Standard No.5 120L Original Standard + 120L standard diluent 
1000ng/L Standard No.4 120L Standard No.5+120L standard diluent 
500ng/L Standard No.3 120L Standard No.4+120L standard diluent 
250ng/L Standard No.2 120L Standard No.3+120L standard diluent 
125ng/L Standard No.1 120L Standard No.2+120L standard diluent 
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           4000ng/L         2000ng/L    1000ng/L   500ng/L  250ng/L    125ng/L 
 
 Washing solution preparation: washing solution is mixed with distilled 
water for the washing steps in ELISA 
 
1. The wells should be marked for blank well, standard well and sample well in 
the ELISA plate 
2. Blank well: no sample is added to tis well, anti YMHAH antibody labelled 
with biotin  or streptavidin-HRP is added. But the chromogen solutions A 
and B and the stop solution should not be added to the blank well 
3. Standard wells: to the standard wells, 50L of the standards of varying 
concentration are added. Then 50L of streptomycin-HRP is added to each 
standard well. The labelled antibody are already added  with the standard 
solution so no need to add the labelled antibody. 
4. Sample well: 40L of sample is added(60 patients sample and 30 healthy 
control individuals serum are added to the respective wells. 10L of 
YMHAH antibodies are added. Then coated with 50L of streptavidin- HRP. 
After addition of the sample and these antibodies. The ELISA plate should 
be sealed and to be shaken gently to mix the contents and then to be 
incubated at 37OC for 60 minutes. 
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5. After the incubation time. ELISa plate is uncovered and dried by blotting 
over filter paper and then washed with washing solution using washer for 
five times and then dried using the filter paper blotting. 
6. Then to each well except the blank well 50L of coloring solution A is 
added, then 50L of colouring solution B is added. Mixed well by shaking 
the plate gently and uniformly. Then the plate is incubated for ten minutes at 
37oC. The plate should be covered and should be stored in a dark place 
avoiding sunlight. Even during addition of the chromogen solutions care 
should be taken to avoid from light. 
7. After the incubation time. Each well except the blank well is added with 
50L of stop solution is added. immediately after adding the stop solution 
the blue colour changes to yellow colour 
8. Within ten minutes of adding the stop solution, the OD of each well should 
be measured at 450 nm wavelength using ELISA reader.  
9. Before hand the ELISA plate should be defined and the concentrations of the 
standars should be fed to the reader. With known concentration of the 
standards, OD is measured and standard graph is plotted. 
10. Using the standard graph,  and the plotting the OD of the samples over the 
graph, the ELISA reader gives the concentration of the different samples. 
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OBTAINING RESULTS USING STANDARD GRAPH: 
 The concentration of the standards are made as the abscissa(x axis ) and the 
OD as ordinate(y axis). Using this graph the unknown concentration of the 
samples are obtained by calculating the concentration using the measured OD. 
 Assay range   :  10ng/L to 3500ng/L 
 Sensitivity   :  5.22 ng/L. 
Intra assay precision  :  CV<10% 
 Inter assay precision  :  CV<12% 
 
ESTIMATION OF c- REACTIVE PROTEIN: 
 CRP is a non specific inflammatory marker. Increases during any 
inflammatory condition and sooner returns back to normal range after recovery. 
 
METHOD : turbidimetric immunoassay 
 
PRINCIPLE: 
 Antigen antibody reaction occurs and the signal is measured by end point 
method. 
 
REAGENT CONSTITUENTS: 
R1 which acts as a buffer contains 
CHEMICAL DESCRIPTION 
Phosphate buffer  pH is 7.43 
Sodium azide 0.09% 
Polyethylene glycol  40g/L 
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R2 antiserum contains 
 
CHEMICAL DESCRIPTION 
Phosphate buffer pH is 7.43 
Sodium azide 0.09% 
Polyclonal goat anti- human for CRP  
 
Reagents are ready to use 
The kit is calibrated using XSYS0053 CRP calibrator. 
Results are obtained automatically not calculated. 
Normal value (given in the kit insert)- 0-10 mg/L or 0-1mg/dl 
Linearity of the kit – upto 22mg/dl 
Lower detection limit – 0.1mg/dl 
Hook effect  >84mg/dl 
Intra -assay precision: CV- 0.82% 
Inter- assay precision: CV-2.46% 
 
ESTIMATION OF URIC ACID: 
 Uric acid is the end product of purines , nucleic acids and nucleoproteins. 
Hyperuricemia occurs in various conditions like renal dysfunction, gout, leukemia 
and many other conditions.  
 
Method: uricase, Endpoint assay. 
 
Principle: 
 Uric acid  is oxidised to allantoin with the help of the enzyme uricase. 
H202 is  also produced in this reaction. The peroxide  reacts with 4-AAP(4- 
57 
 
aminoantipyrine) and TOOS to form a coloured compound quinoneimine dye. 
The absorbance of the dye is measured at 546 nm which is proportional to the uric 
acid level  
                                uricase 
Uric acid + H2O                            allantoin +co2+H2O2 
 
                                           peroxidase 
TOOS + 4AAP + 2H2O2                      quinoneimine dye + 4H2O 
 
Tis reaction is called as trinder reaction. 
 
REAGENT CONSTITUENTS: 
R1 
CHEMICAL CONCENTRATION 
Pipes buffer whos pH is 7.0 50mmol/L 
4- Aminoantipyrine 0.375mmol/L 
Uricase ≥ 200 U/L 
 
R2 
 
CHEMICAL CONCENTRATION 
Pipes buffer whose pH is 7.0 50mmol/L 
TOOS 1.92 mmol/L 
Peroxidase ≥ 5000 U/L 
 
Reagents are ready to use 
CALIBRATION : calibration is done by XL MULTICAL, Cat No. Xsy0034  
CONTROL :  Quality control is checked with ERBA NORM Cat No. BLT0080 
and ERBA PATH, Cat No. BLT00081. 
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REFERENCE VALUES: 
Adult male : 3.5- 7.2 mg/dl 
Adult female: 2.6-6.0 mg/dl 
Linearity is upto 25 mg/dl 
Measuring range is between 0.28-25 mg/dl 
Intra assay precision:  CV of 0.83% 
Inter assay precision:  CV of 1.93% 
 
ESTIMATION OF RHEUMATOID FACTOR(RF): 
 Rheumatoid factor is an auto antibody produced against own 
immunoglobin 
 
PRINCIPLE: 
 Latex agglutination test. Reagent will contain latex particle which will 
coated with human immunoglobin to produce agglutination. 
 
PROCEDURE: 
- After bringing the reagents and sample to room temperature 
- a drop of positive control and patients sample are placed on a slide 
- the reagent containing latex particle is added 
- separate sticks are used for control and sample to mix with the reagent 
- after 2 minutes look for agglutination 
- this is a qualitative test. 
- if agglutination is present in 2 minutes it approximately account for 
more than 18IU/ml 
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DILUTION TEST FOR POSITIVE AGGLUTINATION(SEMI- 
QUANTITATIVE TEST: 
 serial dilutions are made with the positive sample like 1:8, 1:16, 1:32, 
1:64, 1:128 with isotonic saline 
 the qualitative test is repeated with the serial dilution samples and look 
for agglutination. 
 
Result: the last dilution where agglutination is present is noted. 
 
RF in IU/ml= Sensitivity of latex gammaglobulin  x titre where agglutination is 
present. 
Nomal range: less than 15 IU/ml 
 
ESTIMATION OF HEMOGLOBIN: 
METHOD: automated haemoglobin analyser 
 
PRINCIPLE: 
 The blood sample is injected into the analyser through a capillary action. 
The measurement occurs by measuring the absobance of the blood ar a Hb/HbO2 
isoelectric point. The measurement takes place at two wavelengths, 506nm and 
880nm. Two wavelengths are selected to decrease the interference due to the 
turbidity of the sample. The wavelength is also chosen based on the interference 
caused by haemoglobin variants like methemoglobin and carboxyhemoglobin. 
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Type  : quantitative measurement 
Sample : whole blood. 
Precision: For low value with mean of 7.3 g/dL – CV is 0.82% 
 For normal value with mean 13.2 g/dL- CV is 0.80% 
 For high value with mean 17.2 g/dL- CV is 0.78% 
 
ESTIMATION OF ERYTHROCYTE SEDIMENTATION RATE(ESR): 
PRINCIPLE: 
 Anti-coagulant blood on standing in a narrow glass tube for a time period 
without being disturbed, the RBC’s settle down under the influence of gravity. 
The rate of settling of red cells is measured by the millimetres of clear plasma at 
the top of the column. It is measured after one hour and expressed in mm/hr. 
 
METHODS: 
1. Wintrobe’s method 
2. Westergren’s method 
 
PROCEDURE: 
 The blood sample should be mixed thoroughly 
 The blood is drawn into the tube upto 0 mark with the help of rubber bulb 
 Excess blood should be wiped from the bottom of the tube with cotton 
 then the tube is made to stand upright in a stand. Should ensure for any 
leakage from the tube. 
 The tube should be undisturbed for 1 hour 
 After one hour, the result is read 
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REFERENCE RANGE: 
 Males  : 0-10 mm/hr 
 Females : 0-15 mm/hr 
 
ESTIMATION OF TOTAL COUNT: 
 Method: automated cell counter 
  
PRINCIPLE: 
- electrical impedance system(conductivity) 
- direct imaging 
- or flow cytometry 
- electrical impedance is by measuring the changes in the electrical 
impedance produced by the particle while it passes through the 
aperture. 
- Blood cells are non conductive particle and they are mixed with a 
conductive diluent. 
- Along with the conductive diluent while each particle moves through 
the aperture causes an electrical conductance between the electrodes 
which is measured and counted. 
- direct imaging is by when  the blood sample which is diluted while 
passing through a steady steam and a beam of light is focussed on it 
- when each particle passes through the sensing zone, scatters the light  
- scattered light is detected by a photodetector and which is converted to 
electrical impulse and measured 
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- flow cytometry is by when a light of single wavelength is directed over 
a beam of particles, the light being scattered forward or side scatters 
which are detected by photo detectors and measured. 
 
Automated cell counters uses the combination of the principles 
 Normal range : 4000 – 110000 cells/ mm3 
 
False Low count: 
 Leukocyte aggregation 
 
False high count: 
Failure to lyse RBC 
Microclots 
Platelet clumping 
Abnormal hemoglobin 
 
ESTIMATION OF ANTI-CITRULLINATED PEPTIDE ANTIBODY 
(ACPA): 
METHOD: ELISA method 
PRINCIPLE: 
 It is an Indirect solid phase enzyme immunoassay. Quantitative 
measurement of IgG auto antibodies against the citrullinated proteins are 
measured in the serum or plasma. The wells are coated with antigens. The serum 
containing auto antibodies are added to the wells and incubated. After incubation 
the plate is washed to remove the unbound particles. Then an anti-human-IgG 
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horseradish peroxidase conjugate solution is added to each well which will bound 
to the antigen antibody complex. After incubation for binding, the plate is washed 
to remove the unbound particles. Then a chromogenic substance is added to the 
wells. After the development of colour, stop solution is added. The colour turns to 
yellow. The concentration of the colour formed is directly proportional to the 
ACPA concentration present in the sample. 
 
PRECISION: 
Inter assay  :  5.53% 
Intra assay  : 4.70% 
Sensitivity   : even as low as 1U/ml 
Normal range : <15 U/ml 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Statistical Analysis   
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STATISTICAL ANALYSIS 
 
 The data s obtained between the cases and controls were analysed using IBM 
SPSS software 20.  
 The significance was determined when the p value is less than 0.05. 
 The RF, ESR, CRP, ACPA, 14-3-3 eta protein, total count, Hb, uric acid  were 
compared between the cases and the control group using Students t- test. 
 When more than two groups are compared like RF positive cases group, RF 
negative cases group and control groups. One way ANNOVA was done to 
compare the three groups 
 Correlation of parameters between RF, ESR, CRP, ACPA, 14-3-3 eta protein 
are done using pearson correlation. 
 Step wise linear regression was done to find the independent predictor of the 
disease diagnosis. 
 ROC curve was done to determine the specificity and sensitivity of the 
marker14-3-3 eta protein. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results   
S. 
NO
SAMPLE 
NO
AGE / SEX RF ESR CRP ACPA 14-3-3ETA UREA CREAT URIC ACID SGOT SGPT Hb TC
DISEASE 
DURATION
DEFORMITY
1 1 21/F 381 14 7 202 989.5 21 0.8 5.8 30 20 9.8 8700 10 yrs YES
2 2 46/F 164 30 6 56 746.4 23 0.7 6.8 31 15 10.1 8700 5 yrs no
3 3 50/F 128 80 6 55 666.6 21 0.6 2.2 21 22 10.1 6500 3 yrs no
4 4 30/F 123 6 6 45 631.3 22 0.9 3.2 16 3.2 9 9600 3 yrs no
5 8 31/F 478 17 6 396 1565 21 0.6 2.7 30 15 9.6 6700 14 yrs YES
6 11 47/F 135 45 8 55 636 30 1 4.1 25 36 9.9 9600 2 yrs no
7 13 46/F 158 50 24 59 715.8 31 0.8 2.1 26 27 9.8 8600 2 yrs no
8 14 54/F 224 17 6 64 836 25 0.9 1.9 19 22 9.4 6800 4 yrs no
9 32 42/F 460 122 12 321 1321 26 0.8 5.5 26 22 9 10000 3 yrs YES
10 9 39/F 598 29 6 422 1911 23 0.8 2.8 25 35 9.8 7800 13 yrs YES
11 44 57/F 426 15 6 389 1778 20 0.8 3.5 20 21 8.8 7400 11 yrs YES
12 21 31/F 232 55 6 44 657.4 22 0.9 4.5 10 12 8.7 6500 2 yrs no
13 22 38/F 145 24 7 6 501.2 20 0.9 1.3 17 15 11.2 7900 8 YRS no
14 53 44/F 621 29 24 489 1997.3 21 1 2.6 41 31 8 12000 5 yrs YES
15 27 58/F 132 42 5 5 488.9 28 1.2 6.5 30 13 9.2 13300 7 YRS no
16 37 30/F 230 88 16 55 742.6 25 1 32 35 20 9.2 10200 5 yrs no
17 29 43/F 122 45 6 4 514.1 116 0.7 3.1 23 56 12.9 9800 3YRS YES
18 7 48/F 232 18 40 45 600.4 30 0.7 3.4 12 32 11.2 6900 3 yrs no
19 40 38/F 116 72 6 7 485.6 32 11 3.6 36 27 10.2 10200 2 yrs no
20 12 21/F 224 18 6 51 702.6 21 0.8 2.6 30 15 9.8 6700 2 YRS no
21 46 63/F 502 38 12 384 1879 26 1.1 4.2 25 27 9.5 9200 6 YRS YES
22 49 46/F 511 46 6 401 1900.3 25 0.8 1.8 41 24 9.4 6700 11 yrs YES
23 54 35/F 142 58 24 24 667.6 30 0.9 4 33 31 11 10600 3 yrs no
24 55 30/F 132 42 12 26 678.6 55 1 5.2 42 46 10.5 8200 3 yrs no
25 56 51/F 320 62 58 388 1733 55 1 2.6 31 30 13.6 9800 13YRS YES
26 57 40/F 85 62 6 6 551.5 50 1.3 2.9 36 14 11 7900 6MONTHS no
27 25 41/F 140 15 6 56 613.5 24 0.8 1.4 32 21 12.6 9700 10YRS no
28 59 40/F 135 15 6 5 528.2 21 0.6 2.6 35 51 12 6700 5 yrs no
29 60 41/F 132 17 24 4 563.6 25 1 3.4 65 53 11.2 7300 4 yrs no
30 43 39/F 326 35 48 222 964.5 17 1.2 3.7 13 14 1.07 12900 6 yrs YES
RF POSITVE CASES
MASTER CHART
S. 
NO
SAMPLE 
NO
AGE / SEX RF ESR CRP ACPA 14-3-3ETA UREA CREAT URIC ACID SGOT SGPT Hb TC
DISEASE 
DURATION
DEFORMITY
31 5 40/F 5 25 6 4 290.6 31 1.1 4.5 39 18 13.7 7900 2 yrs negative
32 34 29/F 4 55 12 25 402.4 56 0.8 2.3 35 25 12.4 10700 5YRS POSITIVE
33 6 25/F 8 20 24 6 230 23 1 5.5 24 39 10.9 12400 1 year negative
34 10 45/F 7 40 24 5 385.7 20 1 3.6 30 14 10.8 5400 4YRS negative
35 42 45/F 6 70 6 4 220.9 25 0.9 43 30 27 10.1 8600 7 YRS negative
36 18 21/F 3 106 6 6 462.2 19 0.9 2.7 14 17 12.4 8600 6YRS negative
37 19 38/F 2 74 6 5 210 22 0.7 2.7 11 19 10.5 12200 7yrs negative
38 20 45/F 4 70 13 15 544.4 25 1.7 3.2 51 26 12 11300 4 YRS negative
39 23 45/F 7 15 5 4 467.3 26 1 3.5 38 36 10.7 7000 1 YR negative
40 58 45/F 5 64 48 6 256.3 29 1 5.3 10 21 11.8 16100 2 yrs negative
41 26 48/F 4 50 5 6 490.5 17 1.1 1.5 23 26 10.7 8900 1 yr negative
42 30 31/F 8 55 5 5 537.5 35 3.5 2.6 20 30 12.4 11000 6 months negative
43 31 51/F 8 110 6 4 323.7 24 1.2 2.7 41 44 12.4 9500 2 yrs negative
44 15 24/F 2 30 7 6 236.6 22 0.8 3.4 30 15 10 14300 3 yrs negative
45 33 55/F 7 99 8 15 508.7 25 1.1 3.4 13 15 10.6 6900 2 yrs positive
46 35 30/F 4 56 10 6 391.9 26 1.1 3.4 13 15 10.6 6900 2 yrs negative
47 36 30/F 3 16 6 5 437.6 27 1.2 4.7 12 15 12.5 6700 1 yr negative
48 28 42/F 2 100 15 1 233.5 16 1 2.6 35 22 9.9 8400 3YRS POSITIVE
49 38 65/F 5 46 7 4 535.6 32 1.1 3.9 22 12 9.4 12000 5 yrs negative
50 39 45/F 5 18 6 20 410 23 1.1 2.8 25 41 12.8 10100 4 yrs negative
51 41 32/F 4 40 8 12 445.5 24 0.9 2.7 41 21 12.6 6200 4 yrs negative
52 16 39/F 6 35 12 4 230.5 23 0.9 2.8 33 15 10.7 6200 3 yrs negative
53 17 30/F 4 34 12 155 382.7 20 0.7 2.9 26 29 10.2 6900 1 yr negative
54 45 37/F 5 40 8 12 440.3 32 0.9 42 21 14 8.2 6000 2 yrs negative
55 47 50/F 4 40 6 6 518.3 23 1.2 5.4 21 10 11 7000 4 yrs positive
56 48 50/F 6 100 24 16 548.4 23 1 3.1 24 29 9.2 10200 3 yrs positive
57 50 51/F 7 60 48 5 577.3 21 1.2 3.7 31 19 8.2 8600 3 yrs negative
58 51 44/F 8 15 48 4 577.3 19 0.9 3.4 30 21 7.4 6700 3 yrs negative
59 52 42/F 6 29 24 4 504.6 21 0.8 4.8 35 15 8.8 7200 2 yrs negative
60 24 50/F 6 30 8 4 160.3 26 1.5 2.9 14 14 10.2 8100 1 yr negative
RF NEGATIVE CASES
S. 
NO
SAMPLE 
NO
AGE / SEX RF ESR CRP ACPA 14-3-3ETA UREA CREAT URIC ACID SGOT SGPT Hb TC
DISEASE 
DURATION
DEFORMITY
61 1 31/F 5 13 6 3 178 37 0.8 3.1 15 16 13 5500 negative
62 2 32/F 5 14 5 2 261 25 0.7 2.1 25 22 11 6100 negative
63 3 36/F 5 7 4 1 180 24 0.6 4.2 22 23 10.9 7700 negative
64 4 36/F 4 11 4 2 221 28 0.5 3.7 17 16 9.8 5000 negative
65 5 32/F 4 12 4 4 165 27 0.6 3.2 15 16 9.7 4500 negative
66 6 43/F 4 13 4 1 154 29 0.7 3.1 26 15 906 5000 negative
67 7 32/F 2 15 4 2 56 26 0.8 2.8 25 18 9.9 5900 negative
68 8 43/F 2 20 4 3 220 33 0.9 3.5 22 15 10.1 6300 negative
69 9 28/F 2 18 5 4 250 34 1 3.6 15 18 10.2 5500 negative
70 10 26/F 2 17 5 1 54 28 0.8 3.2 25 27 9.8 6000 negative
71 11 26/F 2 18 5 2 380.3 29 0.7 3.1 22 27 11 7000 negative
72 12 29/F 1 19 5 2 180 35 0.6 3.2 28 27 10 4500 negative
73 13 19/F 1 14 5 4 225 28 0.5 2.1 22 27 9.8 5000 negative
74 14 18/F 1 12 6 1 36 25 0.4 3.5 28 29 9.7 5600 negative
75 15 31/F 6 11 6 2 174 26 0.6 2.2 26 25 8.9 6000 negative
76 16 42/F 5 13 6 3 166 24 0.7 2.4 15 14 9.7 4500 negative
77 17 27/F 4 17 6 4 280 28 0.8 2.6 17 18 9.8 5600 negative
78 18 41/F 3 12 6 1 250 29 0.5 2.5 19 18 9.5 4500 negative
79 19 41/F 2 14 4 1 223 32 0.6 2.4 16 17 8.6 6000 negative
80 20 18/F 1 16 5 1 254 34 0.7 2.2 15 18 7.4 4500 negative
81 21 18/F 7 12 4 1 261 38 0.8 2.4 18 19 9.8 4500 negative
82 22 18/F 4 17 5 2 281 26 0.5 2.6 19 17 9.7 4500 negative
83 23 18/F 5 13 4 3 296 27 0.6 2.6 19 18 9.7 5000 negative
84 24 30/F 6 12 6 5 38 28 0.7 2.4 25 27 9.8 6000 negative
85 25 28/F 4 11 6 2 44 33 0.8 3.1 18 19 9.4 7000 negative
86 26 30/F 5 8 4 2 155 27 0.9 3.2 19 19 9.4 6600 negative
87 27 32/F 4 17 4 4 168 29 0.7 3.6 22 26 10.2 5000 negative
88 28 44/f 9 18 4 3 177 36 0.7 2.5 24 29 11 4900 negative
89 29 39/f 5 19 4 5 186 35 0.4 2.8 22 23 9.7 5800 negative
90 30 38/f 4 21 4 2 220 33 0.7 2.6 28 29 9.8 6800 negative
CONTROLS
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RESULTS 
 
TABLE 1: Shows the Age distribution of study Subjects 
Age Group  
(in Years) 
CASE CONTROL 
Number Percentage Number Percentage 
20  - 40 Years 27 45 24 40 
41 -  60 Years 31 51.7 6 10 
Above 60 Years 2 3.3 0 0 
TOTAL 60 100 30 100 
Mean 41.06 31.73 
Standard Deviation 
(sd) 10.09 7.08 
 
 
TABLE 2 : Shows the comparison between the RF value of cases and patients 
 
RF CASE CONTROL 
 Mean Sd Mean Sd 
 131.81 170.71 3.8 1.93 
t-value 5.8 
P-value 0.000 
Significant Significant 
 
 The RF values of cases resulted a mean to be of 131.81 and controls had a 
mean of 3.8. The p value was 0.000( highly significant). 
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TABLE 3: Shows the comparison of ESR between cases and controls 
ESR 
CASES CONTROL 
Mean Sd Mean Sd 
45.8 28 14.46 3.49 
t-value 8.53 
P-value 0.000 
Significant Significant 
 
 The mean ESR of cases is 45.8 and controls is 14.46. and p value resulted 
to be highly significant 
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TABLE-4 : Shows the comparison of CRP between the cases and control 
 
CRP 
CASE CONTROL 
Mean Sd Mean Sd 
13.9 13.18 4.8 0.84 
t-value 5.33 
P-value 0.000 
Significant Significant 
 
 The mean CRP of cases showed 13.9 and mean CRP of controls resulted to 
be of 4.8. the p value resulted to be highly significant. 
 
 
 
 
TABLE-5 : Shows the comparison of ACPA between the cases and control 
 
ACPA 
CASE CONTROL 
Mean Sd Mean Sd 
77.66 134.97 2.43 1.25 
t-value 4.32 
P-value 0 
Significant Significant 
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 The mean value of ACPA of cases was 77.46 and mean of control was 
2.43. The p value resulted to be of highly significant 
 
 
 
 
TABLE-6 : Shows the comparison of 14-3-3 eta protein between the cases 
and control 
 
14-3-3 ETA 
CASE CONTROL 
Mean Sd Mean Sd 
675.45 468.51 191.11 83 
t-value 7.77 
P-value 0 
Significant Significant 
 
 The mean value of 14-3-3 eta protein of cases was 675.45 and mean of 
control resulted to be of 191.11. the p value resulted to  be of highly significant. 
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TABLE-7 : Shows the comparison of haemoglobin values between cases and 
control 
HB 
CASE CONTROL 
Mean Sd Mean Sd 
10.34 1.88 9.18 0.91 
t-value 1.23 
P-value 0.22 
Significant Not significant 
 
 There is no significant difference between the haemoglobin values of cases 
and control. 
 
TABLE-8 : Shows the comparison of total count between cases and control 
 
Total count 
CASE CONTROL 
Mean Sd Mean Sd 
8848.33 2267.79 5560 890.79 
t-value 9.82 
P-value 0.000 
Significant Significant 
 
 The total count resulted to show highly significant difference between the 
cases and the control. 
14-3-3 ETA MEAN
CASES
CONTROL
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TABLE-9 : Shows the uric acid comparison between the cases and control 
 
URIC ACID 
CASE CONTROL 
Mean Sd Mean Sd 
2.82 0.57 2.89 0.52 
t-value 0.54 
P-value 0.59 
Significant Not significant 
 
 There is no significant difference in uric acid between the cases and 
control. 
 
There are significant differences in the values between cases and controls in the 
following parameters: 
1. RF 
2. ESR 
3. CRP 
4. ACPA 
5. 14-3-3 
6. TOTAL COUNT 
 
 Among these parameters total count , esr and crp are not specific markers 
for rheumatoid arthritis. 
 
 They are elevated in all inflammatory conditions and difficult to isolate the 
cause. Rheumatoid factor specific for rheumatoid arthritis. It is a marker showing 
autoimmune role in the disease. Rheumatoid factor leads to cytokine activation 
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and activation of other inflammatory factors and also leads to bone erosion. 
ACPA also a specific marker for rheumatoid arthritis. 
 
 14-3-3 eta protein which is a chaperone protein gets released during 
inflammatory signals and causes matrix metallo proteins to be increased and 
causes bone destruction. 
 
TABLE 10: Shows the comparison of deformities between RF positive cases 
and RF negative cases 
DEFRMITY 
HISTORY 
RF positive RF NEGATIVE 
Number Percentage Number Percentage 
NO 19 59.4 25 78.1 
YES 11 34.4 5 15.6 
TOTAL 30 100 30 100 
Chi-square 32.77 
p-value 0.0001 
Significant Significant 
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TABLE 11: Overall view of the analyte comparison  
between the cases and control 
 CASES CONTROL 
RF% 50 0 
ESR% 75 3 
CRP% 55 0 
ACPA% 41.6 0 
14-3-3ETA% 83.3 3 
 
 The following table shows the positivity percentage of various analyte 
between the cases and control. 
 
 14-3-3 eta protein shows a higher percentage of positivity in cases and can be 
considered as a good marker to identify more cases 
 ESR also determines more percentage of cases. But not specific to rheumatoid 
arthritis. ESR is marker for all inflammatory conditions. 
 CRP also not a specific marker for rheumatoid arthritis. CRP increased in all 
inflammatory conditions 
 ACPA and RF are specific for rheumatoid arthritis but not sensitive. The 
percentage of positivity among the cases is low 
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THREE GROUP COMPARISON 
The study population were divided into three groups as follows: 
Cases were classified into 2 groups. Patients were divided according to RF 
positive cases and RF negative cases. 
RF positive cases  - 30 
RF negative cases - 30 
Healthy control - 30 
 
TABLE 12: Shows the comparison of RF value between the RF positive 
cases, RF negative cases and control 
RF 
RF POSITIVE 
CASES 
RF NEGATIVE 
CASES CONTROL 
Mean Sd Mean Sd Mean Sd 
258.46 161.56 5.16 1.83 3.8 1.93 
F-value 74.12 
P-value 0.0001 
Significant SIGNIFICANT 
 
There is significant difference between the RF values between the three groups 
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TABLE 13: 
Shows the comparison between the ESR values of RF positive cases, RF negative 
cases and healthy control 
 
ESR 
RF POSITIVE 
CASES 
RF NEGATIVE 
CASES CONTROL 
Mean Sd Mean Sd Mean Sd 
40.2 26.42 51.4 28.84 14.46 3.49 
F-value 20.92 
P-value 0 
Significant SIGNIFICANT 
 
There is significant difference between the ESR values of the three groups 
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TABLE-14 : Shows the comparison of CRP values between the two groups 
CRP 
RF POSITIVE 
CASES 
RF NEGATIVE 
CASES CONTROL 
Mean Sd Mean Sd Mean Sd 
13.7 13.59 14.1 12.99 4.8 0.84 
F-value 7.02 
P-value 0.0001 
Significant SIGNIFICANT 
 
There is significant difference between the CRP values of three different groups 
 
 
 
 
TABLE-15 : Shows the comparison of ACPA values between the three 
groups 
 
ACPA 
RF POSITIVE 
CASES 
RF NEGATIVE 
CASES CONTROL 
Mean Sd Mean Sd Mean Sd 
142.86 165.88 12.46 27.41 2.43 1.25 
F-value 19.54 
P-value 0.0001 
Significant SIGNIFICANT 
 
There is significant difference between the ACPA values of the three groups 
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TABLE-16 :Shows the comparison of 14-3-3 eta values between the three 
groups 
 
14-3-3 
ETA 
RF POSITIVE 
CASES 
RF NEGATIVE 
CASES CONTROL 
Mean Sd Mean Sd Mean Sd 
952.21 521.16 398.68 128.41 191.11 83 
F-value 47.23 
P-value 0.0001 
Significant SIGNIFICANT 
 
 There is significant difference between the 14-3-3 eta values between the 
three groups. 
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TABLE-17 : Shows the comparison of haemoglobin between the three groups 
 
HB 
RF POSITIVE 
CASES 
RF NEGATIVE 
CASES CONTROL 
Mean Sd Mean Sd Mean Sd 
9.91 2.11 10.77 1.52 9.89 0.91 
F-value 2.91 
P-value 0.06 
Significant NOT SIGNIFICANT 
 
There is no significant difference between the haemoglobin of three groups 
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TABLE-18: Shows the comparison of total count between the three groups 
 
Total 
count 
RF POSITIVE 
CASES 
RF NEGATIVE 
CASES CONTROL 
Mean Sd Mean Sd Mean Sd 
8763.3 1886.33 8933.33 2624.85 5560 890.79 
F-value 28.91 
P-value 0.0001 
Significant SIGNIFICANT 
 
There is  significant difference between the total count values between the three 
groups 
 
 
TABLE-19: Shows the comparison between the uric acid value of three 
groups 
 
URIC 
ACID 
RF POSITIVE 
CASES 
RF NEGATIVE 
CASES CONTROL 
Mean Sd Mean Sd Mean Sd 
2.77 0.65 2.87 0.48 2.89 0.52 
F-value 0.38 
P-value 0.68 
Significant NOT SIGNIFICANT 
 
There is no significant difference between the uric acid values of the three groups. 
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CORRELATION STUDIES BETWEEN THE PARAMETERS 
TABLE-20: Correlation with RF 
 
 RF POSITIVE CASES 
RF NEGATIVE 
CASES CONTROL 
 r P-value r P-value r P-value 
14-3-3 eta 0.935** 0 0.23 0.23 -0.01 0.96 
ACPA 0.951** 0 -0.14 0.48 0.21 0.27 
ESR -0.03 0.89 -0.11 0.57 -0.27 0.15 
TOTAL 
COUNT 0.02 0.93 -0.16 0.39 0 0.99 
CRP 0.11 0.56 0.36 0.05 -0.11 0.57 
 
Note : ** Correlation is Significant at 0.01  * Correlation is Significant at 0.05 
There is a  highly significant positive correlation between  
 
 RF value and14-3-3 eta protein value in the RF positive cases and there is 
no correlation between the two in other two groups 
 RF value and ACPA value in the RF positive cases and there is no 
correlation between the two in other two groups 
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TABLE-21: Correlation with 14-3-3 eta 
 
ACPA 
RF POSITIVE 
CASES 
RF NEGATIVE 
CASES CONTROL 
R P-value r P-value r P-value 
0.983** 0 0.03 0.86 0 0.98 
ESR -0.01 0.95 0.02 0.9 0.28 0.13 
TOTAL 
COUNT 0 1 -0.25 0.18 -0.17 0.37 
CRP 0.17 0.37 0.17 0.36 -0.18 0.34 
 
Note :** Correlation is Significant at 0.01   * Correlation is Significant at 0.05 
 
There is a highly significant correlation between 
 
 14-3-3 eta protein and ACPA values in the RF positive cases group and 
there is no correlation between the two other groups 
 There is no other correlation between the 14-3-3 eta protein and other 
parameters. 
 
 
TABLE-22: Correlation with ACPA 
 
ESR 
RF POSITIVE 
CASES 
RF NEGATIVE 
CASES CONTROL 
r P-value r P-value r P-value 
0 0.99 -0.09 0.63 0.28 0.14 
TOTAL 
COUNT 0.06 0.74 -0.12 0.52 -0.1 0.59 
CRP 0.21 0.27 -0.05 0.79 0.05 0.79 
 
There is no correlation between ACPA and other parameters 
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TABLE-23: Correlation with disease duration 
 
14-3-3 ETA 
RF POSITIVE CASES RF NEGATIVE CASES 
r P-value r P-value 
0.643** 0 -0.77 0.69 
RF 0.588** 0 -0.35 0.06 
ACPA 0.663** 0 -0.17 0.38 
ESR -0.3 0.1 0.33 0.07 
CRP 0.08 0.67 -0.09 0.64 
TOTAL 
COUNT -0.05 0.81 0.15 0.44 
 
 
There is a highly significant positive correlation between 
 Disease duration and 14-3-3 eta protein values in the RF positive cases 
 Disease duration and RF value in RF positive cases 
 Disease duration and ACPA values in RF positive cases 
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STEPWISE LINEAR REGRESSION ANALYSIS 
TABLE 24: 
Correlations 
 VAR00010 O1433 RF CRP ACPA ESR 
Pearson 
Correlation VAR00010 1.000 -.513 -.400 -.373 -.309 -.544 
 O1433 -.513 1.000 .931 .277 .930 .194 
 RF -.400 .931 1.000 .186 .915 .092 
 CRP -.373 .277 .186 1.000 .219 .221 
 ACPA -.309 .930 .915 .219 1.000 .084 
 ESR -.544 .194 .092 .221 .084 1.000 
Sig. (1-
tailed) VAR00010 . .000 .000 .000 .002 .000 
 O1433 .000 . .000 .004 .000 .034 
 RF .000 .000 . .040 .000 .193 
 CRP .000 .004 .040 . .019 .018 
 ACPA .002 .000 .000 .019 . .217 
 ESR .000 .034 .193 .018 .217 . 
N VAR00010 90 90 90 90 90 90 
 O1433 90 90 90 90 90 90 
 RF 90 90 90 90 90 90 
 CRP 90 90 90 90 90 90 
 ACPA 90 90 90 90 90 90 
 ESR 90 90 90 90 90 90 
 
RF, CRP, ACPA, ESR  and 14-3-3 eta protein shows significant predictors of the 
disease 
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Model Summaryb 
Model R R Square 
Adjusted 
R 
Square 
Std. 
Error  
of the 
Estimate 
Change Statistics 
Durbin-
Watson 
R 
Square 
Change 
F 
Change df1 df2 
Sig. 
F 
Change 
1 .781a .610 .586 .30485 .610 26.243 5 84 .000 .986 
a. Predictors: (Constant), ESR, ACPA, CRP, RF, O1433 
b. Dependent Variable: VAR00010 
 
ESR, ACPA, CRP, RF and 14-3-3 eta protein are considered to be be independent 
predictors of disease 
 
ANOVAa 
Model Sum of Squares Df 
Mean 
Square F Sig. 
1 Regression 12.194 5 2.439 26.243 .000b 
 Residual 7.806 84 .093   
 Total 20.000 89    
a. Dependent Variable: VAR00010 
b. Predictors: (Constant), ESR, ACPA, CRP, RF, O1433 
 
 From the above table from spss software the individual predictors of the 
disease are found to be ESR, ACPA, CRP, RF and 14-3-3. Step wise regression 
analysis is done to predict whether the markers of interest can be used as an 
individual marker for diagnosing the disease or used for prognostic tool.  It is 
based on correlation factors to determine the significance of the individual 
markers and then the predictor characteristics are determined by significance by 
ANNOVA. 
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ROC FOR 14-3-3 ETA PROTEIN 
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Coordinates of the Curve 
Test Result Variable(s): O1433 
Positive if  
Greater Than or Equal Toa Sensitivity 1 - Specificity 
35.0000 1.000 1.000 
37.0000 1.000 .967 
41.0000 1.000 .933 
49.0000 1.000 .900 
55.0000 1.000 .867 
105.0000 1.000 .833 
154.5000 1.000 .800 
157.6500 1.000 .767 
162.6500 .983 .767 
165.5000 .983 .733 
167.0000 .983 .700 
171.0000 .983 .667 
175.5000 .983 .633 
177.5000 .983 .600 
179.0000 .983 .567 
183.0000 .983 .500 
198.0000 .983 .467 
215.0000 .967 .467 
220.4500 .967 .400 
220.9500 .950 .400 
222.0000 .950 .367 
224.0000 .950 .333 
227.5000 .950 .300 
230.2500 .933 .300 
232.0000 .917 .300 
235.0500 .900 .300 
243.3000 .883 .300 
252.0000 .883 .233 
255.1500 .883 .200 
258.6500 .867 .200 
270.5000 .867 .133 
280.5000 .867 .100 
285.8000 .867 .067 
293.3000 .850 .067 
309.8500 .850 .033 
352.0000 .833 .033 
381.5000 .833 .000 
384.2000 .817 .000 
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Positive if  
Greater Than or Equal Toa 
Sensitivity 1 - Specificity 
388.8000 .800 .000 
397.1500 .783 .000 
406.2000 .767 .000 
423.8000 .750 .000 
438.9500 .733 .000 
442.9000 .717 .000 
453.8500 .700 .000 
464.7500 .683 .000 
476.4500 .667 .000 
487.2500 .650 .000 
489.7000 .633 .000 
495.8500 .617 .000 
502.9000 .600 .000 
506.6500 .583 .000 
511.4000 .567 .000 
516.2000 .550 .000 
523.2500 .533 .000 
531.9000 .517 .000 
536.5500 .500 .000 
540.9500 .483 .000 
546.4000 .467 .000 
549.9500 .450 .000 
557.5500 .433 .000 
570.4500 .417 .000 
588.8500 .383 .000 
606.9500 .367 .000 
622.4000 .350 .000 
633.6500 .333 .000 
646.7000 .317 .000 
662.0000 .300 .000 
667.1000 .283 .000 
673.1000 .267 .000 
690.6000 .250 .000 
709.2000 .233 .000 
729.2000 .217 .000 
744.5000 .200 .000 
791.2000 .183 .000 
900.2500 .167 .000 
977.0000 .150 .000 
1155.2500 .133 .000 
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Positive if  
Greater Than or Equal Toa 
Sensitivity 1 - Specificity 
1443.0000 .117 .000 
1649.0000 .100 .000 
1755.5000 .083 .000 
1828.5000 .067 .000 
1889.6500 .050 .000 
1905.6500 .033 .000 
1954.1500 .017 .000 
1998.3000 .000 .000 
a. The smallest cutoff value is the minimum observed test value minus 1, and the 
largest cutoff value is the maximum observed test value plus 1. All the other 
cutoff values are the averages of two consecutive ordered observed test values. 
 
from the ROC analysis it has been determined that 381.5 value is the cut off  to 
diagnose more number of true positive cases and do not include persons are not 
classified as diseased who are not actually diseased. Thus the cut off value 
determines  good sensitivity and specificity. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion   
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DISCUSSION 
 
 Rheumatoid arthritis is a chronic autoimmune inflammatory joint disorder 
affecting multiple joints. The disease progression leads to bone erosion and 
disability96,97. The disease pathogenesis is multifactorial. The recent advances in 
the treatment of rheumatoid arthritis have developed drugs which modify the 
disease progression such as DMARD’s. Intensive treatment of the patients have 
shown significant improvement in the disease. With proper treatment the disease 
progression can be halted and the deformity can be prevented which leads to a life 
long disability. 
  
 Even after centuries the diagnosis of rheumatoid arthritis remain a 
challenging to the physicians. The specific and sensitive markers are not 
satisfying the identification of patients because of the prevalence of significant 
percentage of sero negative patients98.  
 
 Diagnosis is based on a combination of clinical symptoms, clinical findings 
and laboratory investigations. Among the current investigation panel RF is a 
sensitive marker to identify more number of cases whereas anti CCP is a specific 
marker99,100 to identify rheumatoid arthritis patients. 
 
 The lack of sensitivity and specificity of the present diagnostic panel of 
parameters have lead to the research of newer biomarkers to add to the present 
panel to identify more cases and halt the progression of the disease and prevent 
the disability to greater extend. 
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 Hence this study has been undergone to determine the effectiveness of the 
newer biomarker 14-3-3 eta protein to diagnose more number of patients at a 
earlier stage and halt the progression of the disease course. 14-3-3 eta protein 
levels are more correlated to the matrix metallo proteinases which are markers of 
bone destruction process. The synovial fluid determination of 14-3-3 eta protein 
are more specific than the serum. As it is an invasive procedure. Serum levels of 
14-3-3 eta protein have been determined in this study which has been previously 
determined by many studies across the world.   
 
In this study the study population is divided into 3 groups 
Group 1: RF positive patients 
Group 2: RF negative patients 
Group 3 : healthy controls 
 
RF: 
 RF being a sensitive marker. The mean of RF was compared between the 
cases and controls and later with the 3 separate groups. 
 
 The mean RF of cases(131.81) and controls(3.8) and they were 
significantly different(p<0.01) 
 
 The mean RF of positive cases(258.46) and negative cases(5.16) and 
controls (3.8) and were significantly different between the groups(p<0.05) 
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 There are several studies supporting RF as a sensitive marker in the 
diagnosis of rheumatoid arthritis101. 
 
ACPA: 
 ACPA is a specific marker in the diagnosis of rheumatoid arthritis and was 
compared among the groups  
 
 The mean ACPA of  cases(77.6) and controls(2.43) and was significantly 
different(p<0.05) 
 
 The mean ACPA of positive cases(142.86) and negative cases(12.46) and 
controls(2.43) and were significantly different among the groups(p<0.05) 
 
 ACPA is considered as a specific marker and one among the diagnostic 
panel of rheumatoid arthritis.  
 
ESR: 
 ESR  is an inflammatory marker and not specific to rheumatoid arthritis but 
has been used as one among the markers in the diagnostic panel. 
 
 The mean value between the cases and the control showed significant 
difference (p<0.05) 
 
 There were also significant difference among the positive cases, negative 
cases and control groups (p<0.05). 
 
 ESR is a non specific inflammatory marker. 
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CRP: 
 CRP is also a non specific inflammatory marker which is increased in 
rheumatoid arthritis. The CRP value shows statistically significant difference 
among cases and controls and also among the positive cases, negative cases and 
controls (p<0.05) 
 
14-3-3 eta protein: 
 The mean value of 14-3-3 eta protein of cases(675.45) and 
controls(191.11) resulted to significantly different(p<0.05)  
 
 The mean value of positive cases(952.21), negative cases(398.68) and 
controls(191.11) also resulted to be statistically significant(p<0.05). 
 
 14-3-3 eta protein is a chaperone whose expression103 causes inflammatory 
mediators to recruit and causes release of matrix metalloproteinases and 
destruction of the bone joint. The levels of  the new marker 14-3-3 can be equated 
to the bone destruction. Thus can be used as a marker for deformity. And it can 
also be used as an early marker of the joint damage and can be used to prevent the 
progression of the disease. 
 
 There are also animal studies done on dogs demonstrating the high levels 
of 14-3-3 eta protein in the synovial fluid in the dogs with ligament tear104. In the 
animal studies the 14-3-3 eta levels are compared with the matrix 
metalloproteinases and resulted to have a positive correlation between the both 
parameters. 
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CORRELATION STUDIES: 
Correlation studies are done to establish relationship between the parameters 
diagnosing the disease 
 Positive correlation is one in which both the parameters increase or 
decrease simulataneously and the statistical significance is calculated 
 Negative correlation is one in which both parameters show difference in 
the opposite direction. For example for the increase in one parameter the 
other parameter shows significant difference 
 
 Correlation studies are done using SPSS software using pearson 
correlation. 
 
 In my study the various parameters are analysed to determine its relation 
between one another 
 
 Rheumatoid factor which is used as a diagnostic marker for rheumatoid 
arthritis was compared with other analytes in my study and resulted to have 
 
 Positive correlation with 14-3-3 eta protein of RF positive patients which is 
highly significant correlation 
 Positive correlation with ACPA of RF positive patients which is also 
highly significant 
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The new emerging marker 14-3-3 eta protein was compared with the existing 
markers and resulted to have 
 Positive correlation with ACPA of RF positive patients and which is highly 
significant correlation. 
 
 To know the severity of the disease the marker should have the positive 
correlation with the duration of the disease so that with the level of the markers 
can be used as a severity marker of the disease whom are highly prone for 
complications like joint damage and disability. 
 
 14-3-3 eta protein have a positive correlation with the disease duration 
among the RF positive patients 
 RF also has a positive correlation with the disease duration among the RF 
positive patients. 
 
STEPWISE REGRESSION ANALYSIS: 
 Step wise regression analysis is done to determine the efficacy of 
individual markers as predictors of the disease. 
 
Done using spss software using data of the study. It has been resulted that  
- ESR 
- CRP 
- ACPA  
- RF 
- 14-3-3 eta 
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can be used as independent predictors of the disease. But ESR and CRP are not 
specific markers. Both are inflammatory markers which can be elevated in any 
inflammatory conditions cannot be used as  independent markers. 
 
 RF is a sensitive marker but not specific and not all the patients present 
with high RF values. This leads to miss cases to be diagnosed at an earlier stage 
and leads to deformity development 
 
 ACPA is a specific marker of the disease and can be used as a independent 
marker but the sensitivity is low. 
 
 14-3-3 eta protein has diagnosed 83.3% of cases in our study and with step 
wise regression analysis has also been proved that can be used as an independent 
marker. Thus the emerging new marker 14-3-3 eta protein can be used in the 
routine diagnosis of the disease. The combination of 14-3-3 eta protein along with 
the existing markers can be used to diagnose more number of cases at an early 
stage and with the use of current  broad spectrum of drugs rheumatoid arthritis can 
be halted from progression to deformity and disability. 
 
ROC determination for 14-3-3 eta protein: 
 ROC is done to determine the sensitivity and specificity of the marker. And 
it has been determined that  with the cut off value of 381.5, the newer marker has 
good sensitivity and specifity. 
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CONCLUSION 
 Rheumatoid arthritis is a chronic autoimmune disorder inflammatory 
disorder involving joints. It has also extra articular manifestations. This study was 
done to determine the role of 14-3-3 eta protein in the diagnosis of rheumatoid 
arthritis 
 
 The new marker diagnosed 83.3% of patients 
 There was significant difference in the values among the patients and the 
controls 
 There was positive correlation with existing marker rheumatoid factor 
 There was also positive correlation with the disease duration and hence can 
be used to asses the severity of the disease 
 The study also proved that 14-3-3 eta protein can be used as an 
independent marker 
 And the marker has a good sensitivity and specificity. 
 
 Thus our study has proved the role of 14-3-3 eta protein in rheumatoid 
arthritis and have determined its significance which can be used along with other 
markers to diagnose more number of cases at an early stage and halt the disease 
progression. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Limitation of the study 
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LIMITATIONS OF THE STUDY 
 
 14-3-3 eta protein is determined by ELISA procedure which is not a gold 
standard method of determination. 
 Its role has not been determined whether increased in all other 
inflammatory diseases. 
 Its role should be determined in other arthritis like osteoarthritis, psoariatic 
arthritis, and other inflammatory arthritis. 
 
  
 
 
 
 
Scope for further studies   
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FUTURE PROSPECTS OF THE STUDY 
 
 14-3-3 eta protein determination can be used as a early marker for 
diagnosis.  
 Even before the progression of the disease to deformity 
 Its role has to be established using follow up studies to determine its use to 
identify patients even before the clinical arthritis. 
 There are studies done to determine its role as a follow up study105. In this 
study patients with high levels of 14-3-3 eta protein with arthralgia 
developed arthritis in a median period of 15 years. 
 Thus can be used as an early marker even before the onset of clinical 
arthritis 
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ேததி                                              ைகெயா~ப  
  
ஆராvசி தகவ  தா. 
 
 தuகள¢  இர{த இuெப²tெகாள~பyட¢. 
ெச}ைன அர ெபா¢ ம¯{¢வமைனய ¬hUSÁõu®  
÷{õ¯õÎPÎß CµzuzvÀ 14&3&3 Chõ GÝ® ¦µuzvß AÍÄ 
£ØÔ¯ ©¸zxÁ B´Ä” எ}ற தைல~ப ஆராvசி  
நைடெப² வ¯கி}ற¢. 
நuக¶ இ|த ஆராvசிய பuேகக நாuக 
வ¯பகிேறா . 
இ|தஆராvசிய உuக¶ைடயஇர{தஎ{¢ சிற~©~பƬ
ேசாதைனtஉyப{திஅத}தகவகைளஆராேவா. 
 அதனா தuகள¢ ேநாய}ஆவறிtைகேயாஅல¢ சிகிv
ைசேயாபாதி~©tஉளாகா¢எ}பைத­ெதƬவ{¢tெகா
கிேறா. 
 «ºகைள அல¢ க¯{¢tகைள ெவளய ேபாேதா 
அல¢ ஆராvசிய} ேபாேதா தuகள¢ ெபயைரேயா 
அல¢ அைடயாளuகைளேயா ெவளயடமாyேடா 
எ}பைத­ ெதƬவ{¢tெகாகிேறா 
இ|த ஆராvசிய பuேகப¢ தuக¶ைடய 
வ¯~ப{தி}  ேபƬ தா} இ¯tகிற¢.ேம´  நuக 
எ|ேநர« இ|த ஆராvசியலி¯|¢ ப}வாuகலா 
எ}பைத­ ெதƬவ{¢ெகாகிேறா. 
இ|த சிற~© பƬேசாதைனகள} «ºகைள ஆராvசிய} 
ேபா¢  அல¢ ஆராvசிய} «வ}  ேபா¢ தuக¶t 
அறிவ~ேபா எ}பைத­ ெதƬவ{¢tெகாகிேறா. 
 
 
ஆராvசியாளƫ ைகெயா~ப     பuேகபாளƫ ைகெயா~ப 
 
ேததி: 
